1GL

JULY 2017 SESSION Ph.D. Programme

PROSPECTUS

ALL INDIA INSTITUTE OF MEDICAL SCIENCES

New Delhi

IMPORTANT NOTICE

As per direction received from Academic Section, AIIMS, New Delhivide Note No. nil dated 21st July, 2017. The Admission process inPh.D published under Admission Notice No.20/2017 dated 11th May,2017 had to postpone in middle due to increase seats position andintroduce some seats in other subjects/disciplines. Accordingly,afresh Registration process are started w.e.f. 3rd August, 2017 withnew changes.

Those candidates who have earlier applied against the AdmissionNotice No. 20/2017 dated 11th May, 2017 needs to apply afresh due toopening of opportunities in some more subjects/disciplines. However,Registration fees submitted earlier are being refunded in theirrespective Bank Account through RTGS.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

i

IIMMPPOORRTTAANNTT DDAATTEESS AATT AA GGLLAANNCCEEANCE

Last date for Online Registration of Application on AIIMSwebsite www.aiimsexams.org

17.08.2017(upto 05:00 P.M.)

Important Notice1. Please fill the Online Application carefully. It may not be possible to make changes after Registration as

indicated.2. Any Amendment/Rectification/Change/Editing is NOT allowed in Name, Category, Department and OPH

status after submitting the application fee through Debit/Credit Card/Net Banking and images onceuploaded can not be changed later.

3. Other changes in the online Registration/Application i.e. Nationality, Sponsored to General, General toSponsored etc. will NOT be permitted after 17.08.2017.

4. Applicants may note that further correspondence will NOT be entertained in this regard.

Date of Uploading Prospectus and Registration of Online Application throughweb portal.

03.08.2017 Thursday

Last date for Registration of Online application. 17.08.2017 Thursday

Ph.D. Status of application & Rejected application with reason for rejection.

Applicants are required to check on 26.08.2017 through the RegistrationStatus Tab of their My Page after Login.

25.08.2017 Friday

Last date for submission of required documents for Regularization ofRejected Application. No Correspondence will be entertained after 29.08.2017under any circumstances and candidates are requested NOT TO CONTACT theExamination Section.

29.08.2017 Tuesday

Last date for Ministry of Health & Family Welfare, Govt. of India to forward anapproval regarding “No Objection” to the Foreign National for appearing in thePh.D. Entrance Examination for July 2017 session.

29.08.2017 Tuesday

Finalization of Centres and allotment of Roll Nos/Admit Card on website. 01.09.2017 Friday Written Test through online (CBT) modes 08.09.2017 Friday Expected date of declaration of Result 13.09.2017 Wednesday 5Departmental Assessment 22.09.2017 Friday Final result 27.09.2017 Wednesday Last date for joining the Ph.D. Programme 14.10.2017 Saturday

Declaration of ResultsResults for Ph.D. Programme will be available on website at www.aiimsexams.orgResult of individual candidate will NOT be informed on telephone and candidates are advised NOT to call theExamination Section for such information. However, individual result can be checked after closing ofadmission process.Application Fee

General / OBC Category: Rs.1000/- + Transaction Charges as applicable SC/ST Category: Rs. 800/- + Transaction Charges as applicable OPH Candidates is exempted from any Fee

Mode of payment: Through Debit/Credit Card/Net Banking

To facilitate quick redressal of queries use registered email Id of Registration Form. Replies/Clarifications will onlybe given through this email.

All applicants are advised to read the Prospectus and Help Manual carefully before starting OnlineRegistration and ensure that no column is left blank. In the event of rejection of the application form, nocorrespondence/request for reconsideration, will be entertained. Applicants are also advised to download andtake a print of the Registration Form. They should retain a copy of Registration Form till the completion ofAdmission Process.Please visit www.aiimsexams.org regularly for latest notification/announcement as well any Addendum/Dedendum/ Corrigendum/Latest updates etc. regarding this Examination.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LY B

ATCH

201

7PR

OSP

ECTU

S

i

Section Particulars Page No.

I INTRODUCTION 1

II AIMS and OBJECTIVES 1

III Ph.D. Programme

Number of seats, Departments Research Projects, General Eligibility, Duration ofCourse, Centre for Examination, Method of Selection, Rules for admission for inservice candidate leave and other Rules and other terms & conditions etc.

2 - 34

IV IMPORTANT INSTRUCTIONS APPLICABLE TO ALL EXAMINATIONS:

Instructions for filling the Online Application Form 34

Online Registration & Submission of Application Form 34

Status of online Registration & Documents to be Attached with Registration Form 34-35

SUBMISSION OF APPLICATION BY CANDIDATES WHO ARE EMPLOYED 35

Requirements for Admission of Sponsored Candidates 35

Requirements for Admission of Foreign Nationals/Overseas Citizen of India (OCI) 36

Submission of Caste Certificate by SC / ST / OBC Candidates 36

Procedure if there is any Discrepancy Noticed 36-37

V GENERAL INFORMATION 37-39

VI Appendix - I State Code 40

VII Appendix - II Help Manual (Important Instructions for Applicants Filling OnlineApplication Form)

41

VIII Instructions related to Photograph, Signature and Left Thump Impression 42-62

Format of Sponsored Certificate 63

Proforma Prescribed for Other Backward Class (OBC) 64

Form Prescribed for SC/ST Certificate 65

Frequent Asked Questions Enquiries relating to Entrance Examination (FAQs)

CCOONNTTEENNTTSS

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

ii

I.

An Act of Parliament in 1956 established the All India Institute ofMedical Sciences (AIIMS) as an autonomous institution ofnational importance and defined its objectives and functions. Byvirtue of this Act, the Institute grants its own medical degrees andother academic distinctions. The degrees granted by the Instituteunder the All India Institute of Medical Sciences Act arerecognized medical qualifications for the purpose of the IndianMedical Council Act and notwithstanding anything containedtherein, are deemed to be included in the first schedule of thatAct, entitling the holders to the same privileges as those attachedto the equivalent awards from the recognized Universities of India.

In the field of postgraduate and post doctoral education, the mostimportant function of the Institute is to provide opportunities totrain teachers for medical colleges in the country in anatmosphere of research and development. Postgraduate and PostDoctoral students are exposed to newer methods of teaching andgiven opportunities to actively participate in teaching exercises.The other important objectives of the Institute are to bringtogether in one place educational facilities of the highest order forthe training of personnel in all the important branches of healthactivity and to attain self-sufficiency in postgraduate medicaleducation. The educational principles and practices beingadopted are best suited to the needs of the nation.

INTRODUCTIONI

AIMS & OBJECTIVESII AAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BATC

H 20

17PR

OSPE

CTUS

1

1. Seats are available in the following departments :

Sl. No. Department Code No. Numberof SeatsRequired

Sl. No. Department Code No. Number ofSeats

Required101 Anatomy 101 (a) 01

01 **117 Medical Oncology (IRCH) 117 (a) 01

Anatomy 101 (b) 01 118 NMR 118 (a) 01Anatomy 101 (c ) 02 ** NMR 118 (b) 02 **

102 Biophysics 102 (a) 01 119 Neurology 119 (a) 02

Biophysics 102 (b) 01 ** Neurology 119 (b) 01

Biophysics 102 (c ) 02 ** 120 Clinical Neuro Psychology 120 (a) 01

103 Biostatistics 103 (a) 01 121 Neuro Surgery 121 (a) 0101 *

104 Biochemistry 104 (a) 0101 **

122 Orthopedics 122 (a) 01 *

Biochemistry 104 (b) 01 123 Ocular Pharmacology 123 (a) 01

Biochemistry 104 (c ) 01 ** Ocular Pharmacology 123 (b) 01

Biochemistry 104 (d) 01 ** 124 Ophthalmology 124 (a) 01

Biochemistry 104 (e) 01 ** Ophthalmology 124 (b) 03

Biochemistry 104 (f) 02 ** Ophthalmology 124 ( c ) 01 *Biochemistry 104 (g) 01 **

105 CCM 105 (a) 01 125 Obst. & Gynae. 125 (a) 01

106 Centre for Integrative Medicine& Research

106 (a) 02 126 Pharmacology 126 (a) 02

107 Stem Cell 107 (a) 0201 **

Pharmacology 126 (b) 01

108 Dermatology & Venerology 108 (a) 01 Pharmacology 126 ( c) 01Pharmacology 126 ( d) 02 **Pharmacology 126 ( e) 01 **

Dermatology & Venerology 108 (b) 01 127 Physiology 127 (a) 01

109 Endocrinology & Metabolism 109 (a) 01 Physiology 127 (b) 01

110 Division of Forensic Pathology& Molecular DNA (JPNATC)

110 (a) 01 * Physiology 127 ( c) 01

111 Forensic Medicine &Toxicology

111 (a) 01 Physiology 127 (d) 02

112 Geriatric Medicine 112 (a) 01 128 Psychiatry 128 (a) 01

Geriatric Medicine 112 (b) 01 Psychiatry 128 (b) 01

113 Gastroenterology 113 (a) 01 Psychiatry 128 ( c) 01

Gastroenterology 113 (b) 01 129 Pathology 129 (a) 01

Gastroenterology 113 (c ) 01 ** Pathology 129 (b) 01

114 Microbiology 114 (a) 01 Pathology 129 (c ) 01 **

Microbiology 114 (b) 01 130 Pediatrics 130 (a) 01

115 Medicine 115 (a) 01 Pediatrics 130 (b) 0101 **

116 Medical Physics (IRCH) 116 (a) 01 *01 **

Pediatrics 130 ( c) 01

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BATC

H 20

17PR

OSPE

CTUS

2

Ph.DIII

130 Pediatrics 130 (d) 01 * 132 T.I.I. 132 (a) 03

Pediatrics 130 (e) 01 T.I.I 132 (b) 02

131 Reproductive Biology 131 (a) 0101 **

133 Lab Oncology 133 (a) 02 **

Reproductive Biology 131 (b) 01 134 Community Ophthalmology 134 (a) 01 **

Reproductive Biology 131 (c ) 01 **

* AIIMS In Service Candidate

** Candidates having fellowship approved in their name only by Government Organization(s) areeligible to apply for this seat. Self Sponsored Candidate/Candidate with fellowship from

Private Origination(s) are not eligible. No financial commitment of any kind will be on the part ofAIIMS for these seats during entire duration of Ph.D Registration.

2. Departments Research Projects.

Sl.No.

DEPARTMENT CODENO.

REQUIREDQUALIFICATION

BRIEF SUMMARY OF PROJECT

101 Anatomy 101 (a) M.Sc. (Life Science)Biosciences/Biotechnology/Physiology/Microbiology/Biochemistry/Bioinformatics

Project entitled “Evaluation of endemic fluoride associatedanemia during pregnancy in… counseling and intervention

with replacement of safe water- a pilot study”The project is related with fluoride associated resistant

anemia during pregnancy and funded bt DST Govt. of IndiaAnatomy 101 (b) M.Sc.

(Biochemistry/Biotech./Genetics/Life Sciences)

Title: Role of Oxidative Stress and Oxidative DNA Damagein Male InfertilityInfertility is defined as the inability to conceive after one yearof unprotected intercourse by couples of reproductive age.Male infertility is a relatively common condition affectingapproximately 1 in 20 of the male population. As ourknowledge of human reproduction and infertility continues toexpand at a phenomenal rate, it is becoming evident thatoxidative stress (OS) plays a major role. OS is one of themajor contributory factors to sperm DNA damage anddefective sperm function as it damages sperm nuclear andmitochondrial DNA. Many genetic and environmental factorshave been identified to cause defects in sperm functionresulting in OS that impairs the functional and structuralintegrity of the spermatozoa. The reactive oxygen species(ROS) mediated injury to spermatozoa includes peroxidativedamage of the plasma membrane and oxidative damage tomitochondrial DNA, causing impairment of sperm motilityand resulting in abortive apoptosis. There are mechanismsby which the supranormal concentrations of ROS can bescavenged by the anti-oxidants present in the seminalplasma. However, excessive production of ROS or defectsin scavenging machinery lead to OS within the spermatozoathis leads to severe damage in sperm DNA, decrease insperm motility, poor membrane integrity, apoptotic-likechanges and finally, impaired fertilization. Although manynew antioxidants are available to improve infertility, a majorconcern about their usage remains due to lack of scientificevidence supporting their effectiveness.

Anatomy 101 (c ) M.Sc./M..Tech/Life Science/Chemical/Physical Science

Project 1. Magnetic Nanoparticles and Quantum DotsCoupled Visual Confirmation of Cervical Cancer Cellsfrom Cytology Sample: A Cost Effective, Quick andSuitable Test for Rural Indian Setup

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

3

The cause for the development of this cancer is the infectionby high-risk Human papillomavirus (HPV) commonly high-risk types 16, and 18. Among these HPV infections, HPV 16was reported in nearly 86% of cervical cancer patient inIndian population. For the screening and diagnostics ofcervical cancer in India, commonly in practice tests arecervical pap screening, coloposcopy and visual inspectionwith acetic acid. Apart from this, many nucleic acidhybridizations (southern blot, in situ hybridization etc.) andamplification assays (PCR, Real time PCR, microarraysetc.) have been developed. Presently, the gold standarddetection of high risk HPV is US-FDA approved HybridCapture-II from Qiagen, costing approximately Rs 2500/test.This test has good reproducibility (95.3%) and sensitivity(85%) in premalignant/malignant lesions of cervical cancer.However, due to involvement of sophisticated infrastructure,costly testing and requirement of skilled personnel for thedata interpretation, this test is only available in fewesteemed hospitals in India and are not commissioned forscreening as well as diagnostic practices in many primaryand secondary healthcare institution in our country. Thus,the availability of rapid, non-invasive, sensitive and costeffective detection method of transformed cervical cancercells in at-risk women may have the potential to be used forscreening, early diagnosis as well as disease managementduring treatment stage. Bearing this in mind, we propose todevelop a simple, cost-effective and visual detection ofcervical cancer by using magnetic nanoparticles (MNPs)coupled capturing antibody and quantum dot coupleddetecting antibody. These peptides were engineered in silicofrom E7 oncoprotein, which is only expressed in transformedcervical cancer cells after the incorporation of HPV genome.This method will produce a visual fluorescence exclusivelyin the presence of transformed cervical cancer cells in UVlight.

102 Biophysics 102 (a) M.Sc. (Biotech./Biophysics/Biochemistry/Life Science) /M. Biotechnology

This project is about developing saliva based diagnostics forOvarian cancer by discovering a panel of proteomic andmolecular markers. This will lay a foundation for developingnon-invasive and cost effective diagnostics for the routineanalysis in comparison to other diagnostics available fordiagnosis for Ovarian cancer patients.This work will involve identification and validation ofproteomic and Transcriptomics marker at initial stage ofcancer. This study may provide an non-invasive diagnosticsfor cancer patients.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

4

Biophysics 102 (b) M..Sc.(Biophysics/Biochemistry/Biotechnology/Genetics/Chemistry/Microbiology /Life Sciences orMD (Biophysics)

Ph.D Project Description:Tuberculosis (TB) is contagious and one of the most seriousproblem that causes morbidity and death. The poorcompliance due to long treatment regime with anti-tuberculosis drugs has led to the development of multi-drugresistance (MDR) and extensively-drug resistance (XDR) tothis causative bacterium, Mycobacterium tuberculosis. So,there is a critical requirement to discover newer drug targetsand produce anti-tuberculosis drugs to treat drug resistantTB to shorten the treatment duration. The machineryinvolved in bacterial cell wall synthesis and protein synthesisare most popular drug targets for antibiotics. Howevertranslational rescue factors can be new class of potentialdrug targets. During protein synthesis, ribosome stalls dueto truncated mRNA, amino acid starvation or scarcity ofAminoacyl-tRNAs that leads to release of peptidyl tRNAswhich are lethal for cells. Peptidyl tRNA hydrolase (PtH)hydrolyzes the ester bond between peptide and tRNA torescues the cell from toxicity. Hence it is an important drugtarget against bacteria. However, design and developmentof inhibitors against PtH is evading due to lack of knowledgeabout the mechanism of enzymatic activity in the absence ofPtH-substrate complex structure. The main obstacle toobtain PtH-substrate complex is that PtH hydrolyzes thesubstrate immediately as it encounters. So, a non-hydrolysable peptidyl-tRNA, which mimics the substrate, canform a stable PtH-substrate complex to understand thecatalytic mechanism. Another setback is homogeneity of thepeptide length on the tRNA to obtain better crystalscomplexes for better diffraction. By making non-hydrolysableand specific peptidyl tRNA using flexyizyme technology willaddress both of these problems. Aim of the project proposalis to generate a non-hydrolysable peptidyl-tRNA and itscomplex of PtH using small in vitro evolved ribozymesknown as flexizyme. The method involves use of flexizymesto charge a tetra-peptide onto tRNAs having 3′ NH2 ribosegroup at CCA end. The resulting non-hydrolysable peptidyl-tRNAs will then be mixed with bacterial PtH to obtain PtH-substrate complexes for structural studies. The alternative isa hybrid method of Flexizyme technology and cell-freeprotein synthesis system reconstituted from highly purecomponents of the translational machinery of E.coli togenerate non-hydrolysable peptidyl-tRNA. Structuralanalysis of such complexes will help to elucidate thecatalytic mechanism of PtH. This work will open newwindows to design novel antibiotics to target the petidyltRNA hydrolase to treat the tuberculosis.

Biophysics 102 (c ) M..Sc(Biophysics/Biochemistry /Biotechnology/Genetics/Chemistry/Microbiology/Life Sciences orMD (Biophysics)

The project involves study of potential drug target from

Salmonella Typhi. The project involves structural and

biophysical characterization of bacterial cell division protein

FtsZ from Salmonella enterica. The major objectives of the

project involves cloning, expression, purification and various

biophysical techniques the study the bacterial cell division

FtsZ. Major objective of the project will be structure based

ligand screening against FtsZ.

103 Biostatistics 103 (a) M.Sc. (Statistics/Biostatistics India contributes to the highest number of deaths amongchildren under-five in the South Asian region (2.1 milliondeaths in 2006) and one-fifth of under-five deathsworldwide. In comparison with countries having similar

socioeconomic conditions, India’s current under-fivemortality rates are still alarmingly high despite of significantprogress in under-five child mortality (U5MR) indicators in

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

5

the last two decades. Moreover, improvements in childmorality have been uneven and the brunt of high childdeaths is borne by the marginalized and sociallydisadvantaged section of the population. Not only are thesocioeconomic inequalities very high, there are largeregional disparities as well; the northern states depictingmuch higher levels compared to the southern and westernstates with intra-state disparities too. Child mortality studiedusing only a broad-set of individual, household level andcommunity level socioeconomic and environmental riskfactors ignoring the effect of geographic space. Suchanalysis assumes that the relationship between deprivationand mortality is homogenous and uniform over space.However, the findings of studies

documenting relationship between deprivation and mortalityover space are mixed with some studies documentinghomogeneity and others documenting heterogeneity. So,overlooking the spatial correlations may or may not bias themodel results depending on the magnitude of suchcorrelations over time and tends to exhibit a remarkablegeographical pattern/spatial clustering. Literature search onthe topic yield few studies study that takes into accountgeographical/spatial patterns while studying (U5MR) in Indiabut they didn’t study the nonlinear effect of these factors. Tounderstand this important research gap in demographic andepidemiological literature, we attempt to examine whetherthe geographic regions which are underprivileged in terms ofwealth, female literacy, child nutrition, or safe delivery etcwere also grappling with the elevated risk of child mortality;whether there are any spatial outliers and change overhistorical time periods. The present study is to identify riskfactors associated with child mortality such as individualfactors and geographic location. These factors are bestcapture by spatially varying processes. The generalisedlinear model is classified as a spatial generalised linearmodel. We apply GLMM with spatially correlated randomeffects proposed by Hennerfeind et.al, (2005) and used it toanalyze factors associated with child survival in the first 5years of life. This modelling approach falls within a grouptermed structured additive regression (STAR) models,introduced by Kamman and Wand. STAR models are acomprehensive class of models which permit simultaneousestimation of nonlinear effects of continuous covariates, withboth spatially unstructured and structured components,together with the usual fixed effects in the predictors.

104 Biochemistry 104 (a) Master in Biochemistry/Biotechnology/Genetics/Biomedical Science/Nutritional Sciences &Applied Nutrition/Life Sciences orMD in Biochemistry

Cathepsins being a heterogeneous group of proteases thatare ubiquitously present in the nature. Physiologicalfunctions of the cathepsin family include protein turnover,neovascularization, antigen presentation, cell growth andtissue homeostasis. These functions are altered in manypathological conditions including cancer and other ECMrelated pathologies. Therefore, the major focus of ourlaboratory is to understand the molecular regulation of theseproteases particularly cathepsin L and B in severalmalignancies including gliomas, leukemia and gall bladdercarcinoma. Another major focus of our laboratory is toinvestigate the biomarkers of gall bladder cancer foridentifying the most at-risk population, early detection of thisdisease using high-throughput genomics. Further, there isan ongoing investigation of clinical significance of PTENregulated genes in human primary glioblastoma. We aim toanalyze the expression of PTEN regulated genes in braintumor cells in relation to p53 status and investigate theirprognostic significance. We are also studying the molecularmechanism underlying the upregulation of RNA bindingprotein hnRNPD in the pathogenesis of oral cancer. Oralsquamous cell carcinomas (OSCCs) comprise a largeproportion of HNSCCs. The differential-expression analyseswere performed on homogenates of HNOSCC, normalnonmalignant and OPLs (dysplasia) tissues. hnRNPD wasidentified one of differentially expressed proteins in

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

6

HNOSCC patients samples. hnRNPD is involved in manycellular processes such as mRNA splicing & stability,transcription, translation, chromatin remodeling, andtelomere maintenance etc. We have reportedoverexpression of hnRNPD in human oral premalignantlesions and oral cancer tissue by various techniques likeIHC, western blotting and real time quantitative PCR etc andestablished a strong association of hnRNPD overexpressionwith poor prognosis in oral cancer. Therefore, the presentstudy has been designed to elucidate the role and regulationof human hnRNPD in oral carcinogensis.

Biochemistry 104 (b) M.Sc. (Biochemistry/Biotechnology/Genetics/Biomedical Science OrMD in Biochemistry/M.Sc. in Nutritional Science/Applied Nutrition

HDL is one of the key lipoproteins in the circulation and isassociated with a protective function with respect tocardiovascular risk. This is due to the ability of HDL particlesto promote cellular cholesterol efflux from lipid-ladenmacrophages and other pleiotropic protective effects suchas protective effects on vascular wall through potent anti-inflammatory and antioxidant mechanisms and themodulation of vascular endothelial function. The primarydeterminants of key HDL functions are the associatedlipoproteins such as Apolipoprotein A, C others present insmaller amounts, Lecithin Cholesterol AcetylTransferase(LCAT) and Cholesterol Ester Transfer Protein(CETP). It has been observed that changes in altitudemodulates the lipid profile and leads to a change in differentlipoproteins including HDL. A recent study in India has alsoshown that different ethnic groups respond differently to highaltitude with regard to modulation of the lipid profile. SinceHDL affects cardiovascular and vascular function in differentways, it would be interesting to explore whether some of theobserved changes in vascular function e.g. pulmonaryarterial pressures and right ventricular functions arecorrelated with changes in HDL and lipid profile as well asthe inflammatory markers. Therefore, the proposed studyintends to evaluate metabolic alterations and their effect oncardiopulmonary & vascular responses as relevant to HDLfunction during and after subjects have been exposed tohigh & extreme altitudes.Currently funded Projects:A. Population Prevalence of Vitamin D deficiency in Urban

and Rural Delhi and its Association with CardiovascularDisease Risk factors (2016-2018)

B. Dietary diversity and nutritive value of indigenous foodsin addressing food security and nutritional status ofvulnerable tribal communities of India (2017-2022).

Biochemistry 104 (c ) M..Sc.(Biochemistry/Biotechnology/Genetics/Biomedical Science orMD in Biochemistry

Project Summary:Hypoxia, omnipresent in solid tumors, leads to developmentof clinically relevant phenotypes in tumors (resistance,stemness and invasiveness).A study from our lab has shown severe hypoxia inducedMenaInv, a hyperactive isoform of an actin binding proteinMena, to be a major regulator of migration and stemness inhigh-grade glioma cell lines and tumors.We have also communicated that severe hypoxia inducedupregulation of another actin and Mena/VASP interactingprotein, FAT1, in glioma cell lines promoted migration oftumor cells.There are reports in literature about hypoxia induced RhoAsignalling modulating FAK (Focal Adhesion Kinase) pathwayleading to altered actin ploymerization and Mena alsocontributes in this.We have made a preliminary observation about differentialrate of uptake of PLGA nanoparticles under hypoxia.

Biochemistry 104 (d) M..Sc. (Biochemistry/Biotechnology/Genetics/Nutritional Science andApplied Nutritional/Life Science OrMD in Biochemistry

Our lab is involved in cancer biology research of MultipleMyeloma, Bladder Cancer and Cervical Cancer for last twodecades. We are focusing on tumor microenvironment usingECM proteins, SLRPs, shelterin complex, etc for thetargeted therapy. The biomarkers for the early diagnosis andbetter prognosis of various cancers are also one of theleading areas. In the proposed project, we are focusing onhematological malignancies which are one of the deadlydiseases across the globe and necessitate the identification

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

7

of suitable treatment regimen. Currently, chemotherapeuticdrugs are being used for the treatment of hematologicalmalignancies but their inefficiency in combating the diseasealong with the associated side effects generates an urge tofind some safe and effective treatment modality. A unaniherbal formulation has been recognized for its role indetoxification and carcinogen metabolism from the pastmany years. It has been used for the treatment of certaindiseases with minimal side effects. In the proposed study,we aim to investigate the anti-cancer potential of habb-e-asgandh against haematological malignancies (MultipleMyeloma and Chronic Myelogenous Leukemia). In order toachieve this goal, primary bone marrow cells of cancerpatients and cell lines will be treated with herbal formulationalone or as a combinatorial approach with currentlyemployed chemotherapeutic drugs to evaluate the anti-cancer effects of this unani preparation. The anti-cancerefficacy of this formulation will be evaluated in vivo inxenograft mice model of MM and CML. This study might bea step towards utilization of unani formulation as an adjuvantin chemotherapy for the treatment of haematologicalmalignancies with lesser side effects.

Biochemistry 104 (e) M..Sc.(Biochemistry/Biotechnology/Genetics/Biomedical Science/Nutritional Science andApplied Nutritional/Life Science OrMD in Biochemistry

Project Code: ECF04Leukemia is the most common childhood cancer in Indiawith acute lymphoblastic leukemia of B-cell origin (B-ALL)being the commonest. B-ALL is characterized by specificgenetic aberrations including ETV6-RUNX1 (commonest),BCR-ABL, E2A-PBX1 and MLL gene translocations.IGF2BP1 is an oncofetal protein overexpressed in multipleepithelial tumors. Our lab has identified IGF2BP1, an RBP,to be highly expressed in B-ALL with ETV6-RUNX1translocation. The role of IGF2BP1 role in B-ALL isunexplored. ETV6-RUNX1 translocation alone is insufficientfor leukemogenesis. Given its oncogenic role in othercancers, our project will explore the hypothesis thatIGF2BP1 overexpression synergizes with ETV6-RUNX1 tocause B-ALL. Our research study also focuses aroundidentifying the pathogenesis behind this translocationleading to B-ALL. We will also study whether IGF2BP1overexpression correlates with a poorer clinical outcome inB-ALL. In vitro, we will characterize target mRNAs ofIGF2BP1 identified previously by iCLIP-Seq and study thegene network regulated by it. In vitro, we would alsooverexpress/knockdown IGF2BP1 using lentiviral vectorsand study their effect on cell proliferation, apoptosis andchemotherapeutic response. By answering these keyquestions, our study will prove whether IGF2BP1 and itstargets can be used as a novel therapeutic target as well asa prognostic biomarker.

Biochemistry 104 (f) M..Sc. (Biochemistry/Biotechnology/ Genetics/Biomedical Science/Nutritional Science andApplied Nutritional/Life Science OrMD in Biochemistry

Project -1: Epithelial Ovarian Cancer (EOC) is a lethalgynecologic malignancy-affecting woman around the worldand particularly in India. EOC consists of five distinctsubtypes, of which the most lethal high-grade serouscarcinoma (HGSC). The research idea is to investigateHGSC in pursuit of developing a new and highly neededbiomarker for EOC. POTE gene family is a newly found CGantigen and selectively expressed in the prostate, ovary,placenta and testis and termed POTE. Based onpreliminary data it has metastatic potential as well as strongimplications in vaccines against EOC. Key goal is to definethe role of POTE in EOC in order to apply this informationfor the development of a selective biomarker andimmunotherapeutic target. These potentially paradigm-shifting studies contribute towards successful utilization ofPOTE antigens as biomarkers and immunotherapeutictargets.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

8

Project -2: Cancer cells are characterized by alteration in allor most of the factors which normally regulate the genome

architecture, but the role of chromatin state in regulatingspatial organization in cancer is still unclear. The mostimportant features of this spatial chromatin organization isformation of repressed chromosomal domains; LaminaAssociated Domains (LADs)/ Pericentromeric AssociatedDomains (PADs) these domains are preferentially localizedon the nuclear periphery. Prostate, Placenta, Ovary, Testis(POTE) antigen is a newly identified Cancer testis/germlineantigen and localized on pericentromeric regions. Theresearch Idea is to explore the role of 3D nucleararchitecture as an epigenetic regulator in of pericentromericgenes regulation. We are focusing to understand theepigenetic regulatory role of LADs/PADs, in regulation ofpericentromeric localized CT/CG antigen POTE expressionin ovarian cancer. Finally, we believe that outcomes of thisproposed project will enlightenment our knowledge aboutrole of nuclear architecture in regulation of cancer-testis/germline POTE antigen as well as in understandingthe etiology and clinicopathology of ovarian cancer atmolecular level.

Biochemistry 104 (g) M..Sc. (Biochemistry/Biotechnology/ Genetics/Biomedical Science/Nutritional Science andApplied Nutritional/Life Science OrMD in Biochemistry

Project Summary

The broad objective of this project is to investigate theassociation of parasite metabolites, their derivates and theenzymes of the Plasmodium purine salvage pathway withsevere and uncomplicated malaria. Severe malaria occurswhen Plasmodium infections elicit a heightenedproinflammatory response from the human host leading toseveral complications such as severe anemia, multipleorgan dysfunction, coma (in case of cerebral malaria) andmetabolic acidosis. In uncomplicated malaria, the intensityof the inflammatory response is lower in comparison to SMand is not associated with any of the above features. Whileit is well understood that malaria infection leads to distinctdisease outcomes such as severe and uncomplicatedmalaria, and that the disease outcome is governed by host-parasite interactions, the specific host-parasite interactionsthat are involved in these differential disease outcomes arenot known. The present study will investigates the role ofparasite-derived metabolites hypoxanthine and uric acid,known to be pro-inflammatory molecules, with theoccurrence of severe malaria. This will be carried out in boththe prevalent malaria parasite species- Plasmodiumfalciparum (P.f.) and Plasmodium vivax (P.v.). Hypoxanthineis an intermediate in the parasite purine salvage pathway,that relies on import and conversion of extraparasitic purinesto hypoxanthine and its subsequent utilization for ATP andGTP formation. P.f., the causative agent of cerebral malaria,has been shown to accumulate Hypoxanthine during its lifecycle in the mature human RBC. Hypoxanthine is releasedinto the bloodstream upon RBC rupture and converted intouric acid by human xanthine oxidase. Uric acid is a pro-inflammatory molecule and has been linked to diseaseseverity. Whether this is a mechanism by which parasiteselicit the heightened immune response associated withsevere malaria, is not known. The role of this pathway insevere disease of P.v. has never been investigated.

The experimental procedures to achieve these objectiveswill be as follows:

(i) measurement of plasma hypoxanthine and uric acid,(ii) measurement of intraparasitic hypoxanthine and uricacid,(iii) measurement of enzyme activities of PfHGXPRT andhuman Xanthine Oxidase. The study groups will be Healthycontrols, Severe malaria (P.f., and P. v) and UncomplicatedMalaria ( P.f. And P. v.).

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

9

Inhibitors of enzymes in the parasite purine salvage pathwayare under development by several groups in the world, asevidenced by literature. Therefore identification of the role ofthis pathway and its metabolites in severe malaria canpotentially have direct impact in control of inflammationduring severe disease, which may save lives.

105 CCM 105 (a) MBBS/BDS/Master in Public Health

I am presently working as Professor & Head in the Centrefor Community Medicine. I am currently working on researchrelated to interest in Influenza among children and elderly,Non communicable diseases, Effects of pollution and causeof deaths. Presently there are two projects on influenza (NI-1339 and NI-1427) and another five year project is underreview. Projects on pollution, cause of death both of 3 yearsduration and non-communicable diseases (survey whichwould be repeated every five years) have been approved byfunding agency but are under ethics review and are likely tobe operational by May 2017. All these projects have scopefor funding all Ph.D related work of the proposed seat.

106 Centre forIntegrativeMedicine& Research

106 (a) Bachelor in Yoga &Naturopathic Sciences/M. Sc (Biomedical Science)

RESEARCH INTEREST OF THE GUIDEPsychological stress has been studied extensively to causehuman malady. Regardless of heaps of evidence linkingphysical manifestations of stress and cardiovascular diseasein the literature, cardiovascular risk management hasremained focused on other risk factors.Yoga, an ancient Indian traditional medicine, is described asa rich treasure of physical and mental techniques that canbe effectively used to create physical and mental well-being.Mechanistic explanations for yoga’s potential mental andphysical health benefits have highlighted reductions insympathetic nervous system tone and vagal predominance,both of which could have favorable endocrine and immuneconsequences, including lower inflammation.In our center, we study the safety, feasibility, and efficacy ofYOGA intervention on pathophysiological mechanismsinvolved in cardiovascular diseases. Our aim is to envisageyoga, as evidence-based cardiac preventive andrehabilitative measure. Our ongoing projects are titled;“Efficacy of YOGA in Indian patients with Coronary ArteryDisease” (YOGICAD) and “Efficacy of Yoga-Based CardiacRehabilitation on clinical outcomes in post-CABG patients: ARandomized Control Trial”.

107 Stem Cell 107 (a) M.Sc. (Life Science/Biochemistry/Biotechnology/Zoology/Immunology/Genetics

1. Sculpturing corneal constructs usingmicropatterened surface and decellularizedcorneas (N-1523)

2. Targeting Telomerase Reverse Transcripatase(TERT) gene to immortalize Peripheral BloodMononuclear Cells of patients with coronary arteryDisease (I-889)

3. DBT: Centre of Excellence For Stem CellResearch: Basic And Translational (Phase-II)

4. Understanding the therapeutic role of adult stemcellderived exosome in combating virus inducedneurodegenerative disease.

108 Dermatology &Venerology

108 (a) M.Sc. (Microbiology) I have undertaken teaching and research work in the field ofdermatology, Venereology and leprology. Most significantwork has been in the immunopathogenesis, diagnosis andtreatment of vesicobullous diseases especially pemphigusvulgaris, psoriasis, dermatopathology, phototherapy andlasers, hair and nail disorders and vascular malformations.We were the first researchers in the country to utilize ELISAtechnique for detection of pemphigus antibodies and useextracted pemphigus antigens by immunoblot assay fromhuman skin for the diagnosis of pemphigus vulgaris. Theconventional treatment by steroid-sparing agents namelycyclophosphamide pulse and mycophenolate mofetil and

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

10

now the efficacy of new biological agent rituximab. we arealso undertaking research work on the immunology ofpemphigus to comprehend the involvement of Th1,Th2,Th17, Treg cells and dendritic cells in the modulation ofacantholysis and production of pemphigus lesions. Inpsoriasis, we are assessing the clinical and immunologicalutility of biological drug etanercept over conventionaltreatment, I was one of the members to formulate NationalTreatment guidelines for this condition.

Dermatology &Venerology

108 (b) M.Sc. (Life Science/Biotechnology/Biochemistry/Microbiology

Working primarily in the field of Vitiligo, Dermatosurgery andSexually transmitted infections. He has over 150 publishedpapers in his name in indexed journals and received AIIMSexcellence awards-first in clinical sciences 2013 and secondin clinical science 2015. He has introduced many new andfollowing novel procedures in cell-based therapies in vitiligo.1. Use of extracted hair follicle outer root sheath cellsuspension in vitiligo. 2. In-vivo harvesting of epidermal cellsuspension for transplantation in vitiligo.

109 Endocrinology &Metabolism

109 (a) MBBS The investigator has keen interest in the management ofhypocalcaemia disorder especiallya) hypoparathyroidism (Idiopathic)b) He has keen interest in understanding the pathogenesisof Idiopathic hypoparathyroidism & its complications andalso the unique clinical features of the disease. His currentwork is on complications of Idiopathic hypoparathyroidismsuch as basal ganglia calcification, cataract etc.1. Complete project details:• Project code number - N1643• Duration of the project - 3 years (22.01.16 to 21.01.19)• Funding agency-Department of Biotechnology (DBT)2. Availability of position in project- Senior Research Fellow(SRF)

110 Division ofForensicPathology &Molecular DNA(JPNATC)

110 (a) M.Sc.(Physical Anthropology)

Project Title: Post Mortem Histopathological study of postTBI induced axonal injury using silver and AβPP stains incorpus callosum, brain stem and Thalamus

One of the leading causes of death and disability worldwideis brain trauma. It can cause structural, physiological orfunctional changes in the brain that may yield various long-lasting cognitive, neurological and behavioral symptoms.The consequences of brain injury can affect various aspectsof our lives including our personal and mental abilities.Diffused Axonal Injury (DAI) has emerged as most commonand important pathological features of traumatic brain injury(TBI).For rendering a variety of physical and biological featuresvisible silver staining technique has been used in numerousways. The objective of this study is to detect and studyconduct detailed microscopic examination of axons that aredamaged in cases of diffused axonal injury using silverstaining technique as the silver stain gets impregnated withthe neurons along the entirety, that even the minute detailsof dendrites and axonal processes can be revealed.

111 ForensicMedicine &Toxicology

111 (a) M.Sc. (Forensic Science/Biotechnology/Molecular Biology

Research interest:Suicide biology, particularly association of SNPs andinflammatory markers with suicide.

Ongoing projects:An ICMR funded extramural project titled “Bioinformaticsidentification and ‘’invitro evaluation of single nucleotidepolymorphisms associated with completed suicide in Indianpopulation’’

Funding (Apprx. Cost 69 Lakhs, duration 3yrs

(For the year 2017-2018, 1st instalment of Rs.22,74,780/-has been released)

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

11

Fellowship-AvailableIn the project a Research Assistant with minimumqualification Masters degree has been sanctioned.(SalaryRs. 31,000/per month)

112 GeriatricMedicine

112 (a) M.Sc. (Life Science) Biomarker of frailty, ageing and age-related diseasesDr AB Dey has guided 4 MD thesis on frailty. The nextproject will focus on biomarkers at cellular and sub-cellularlevel to detect frailty and other age associated pathologies;such as sarcopenia, dementia etc. The project will beharmonized with NIH funded project “LASI- DAD” forestablishing new norms for diagnosis of frailty and other ageassociated pathologies. The proposed Ph D position will befor research on frailty; which will investigate development ofnew markers of ageing process with special emphasis onfrailty.

GeriatricMedicine

112 (b) MA (Psychology) a. Frailty: - His thesis was on frequency and risk factors offrailty in hospital settings. He has studied as co investigatoron diet and physical therapy as a model to prevent thedevelopment of frailty in AIIMS. Presently he is working onhow to predict frailty early through his intramurally fundedproject “Predicting frailty in Indian hospital settings;comparison of three indicators”. He is also working ondevelopment of “self reported health risk score” assessmentfor community elderly in association with National Institute ofhealth and family welfare.

113 Gastroenterology 113 (a) M.Sc. (Microbiology/Biotechnology/Molecular Biology)

I am presently working as Associate Professor in theDepartment of Gastroenterology. I have interest in liverdisease- hepatitis C, non-alcoholic fatty liver disease,hepatic venous outflow tract obstruction. Presently I aminterested in studying the resistance associated variants(RAVs) in hepatitis C. Oral direct acting agents have beenrecently available in the Indian market are associated withhigh cure rates. Few patients do not respond to the therapyand may have resistance at baseline or may developresistance after therapy. The present project is for 3 yearsand is funded by Department of Health Research (DHR),Government of India. You are expected to develop assaysand assess the RAVs. The department has facilities(including equipments) for conducting the project. Thereagents required for the project will be funded by the DHR.

Gastroenterology 113 (b) M.Sc.(Life Science/Biotechnology/Biochemistry/Master in VatenarySciences

My current research focuses on Molecular biology ofhepatitis viruses, chronic liver disease and hepatocellularcarcinoma. My research on hepatitis viruses includemolecular epidemiology of HBV, HCV and HEV; genotyping,drug resistance mutants, viral diagnostics and effect of hostgenetic factors on hepatitis virus infection and therapeuticresponse. The current project which is approved for fundingby DBT will focus on understanding of HCV immuneresponse, development of replicon model, epidemiology ofHCV and development of viral vectored vaccine by usingreverse genetic approach.

Gastroenterology 113 (c ) M..Sc -Life Sciences/Biochemistry/Biotechnology/Food & Nutrition or MBBS

To study the gut mucosal injury in severe acute pancreatitisand their correlation with organ failure and mortality

114 Microbiology 114 (a) M.Sc.- Life Science 1. Project Title: Early detection of Haemophilus ducreyi,Treponema pallidum, Herpes Simplex Virus type 1 and 2from patients with genital ulcer disease by Multiplex PCR ina tertiary care hospital.Funding Agency: ICMR,Duration: Three years. 15th March’2017- 16th March’2020.

Funds: Rs.37, 63,410 lakhs.Project Code: I- 933ICMR Code: 5/3/3/24/2012-ECD-I

Post Available: Senior Research Fellow (Non-Medical)

Research Areas: Diagnostic Microbiology, AntimicrobialResistance, Molecular characterization of nosocomialpathogens viz., Staphylococcus aures, Enterococcus

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

12

faecalis, Enterococcus faecium and sexually transmittedagents viz., Genital Mycoplasmas and Chlamydiatrachomatis etc.

PhD students registered : 01PhD students to be advertised : 01

Microbiology 114 (b) M.Sc.- Life Science I am working in the field of Medical Mycology. My researchareas include molecular diagnosis and epidemiology ofinvasive fungal infections including aspergillosis,mucormycosis, and cryptococcosis etc. especially inimmunocompromised patients. In addition I also work in thefield of emerging drug resistance in fungi by utilizingconventional antifungal susceptibly testing as well asmolecular techniques.

115 Medicine 115 (a) M.Sc.-Botany I am presently working as Professor in the Department ofMedicine. Presently I am working on Role of Vitamin D inprevention of relapse of CAT-I TB. The two projects VitaminD and TB are funded by DHR.

116 Medical Physics(IRCH)

116 (a) M.Sc. (Physics/Medical Physics/Medical Radiation Physics/Radiation Physics/Radiological Physics

Medical Physics Unit is actively working in the area ofDiagnostic Medical Physics which includes radiationdosimetry in patients and in medical procedures, thedevelopment of suitable radiation dosimeter for the specificsituation, optimisation of radiation in medical imaging,enhancement of capability of medical imagers, study ofradiobiological effects in medical radiation, qualityassurance tests of medical equipment and radiation safetyof patient, staff and public.

117 MedicalOncology (IRCH)

117 (a) M.Sc. (Biotechnology/Biochemistry/Life Sciences

1. Immune Reconstitution following AutologousHematopoietic Stem Cell Transplantation• Autologous hematopoietic stem cell transplantation(AHSCT) is an important therapeutic modality in thetreatment of malignancies.• Peripheral blood stem cell transplants (PBSCTs) accountfor almost all AHSCTs done worldwide.• Immune reconstitution refers to the process by which thevarious components of the immune system recover afterAHSCT.• Components of the acquired immune system may takeseveral months to years to recover. Since protection frominfections depends on a numerically and functionally intactimmune system, patients remain at high risk for severalinfections in the time after transplantation.• Patients with faster lymphocyte reconstitution are expectedto have a lower risk of such infections.• Identification of patients who are at risk for delayedreconstitution may allow better selection of infectionprophylaxis and surveillance strategies for such patients.2. Conditioning Regimens in Allogeneic Stem CellTransplantationa. Alteration of sequence of Busulphan andCyclophosphamide and its effect on transplant relatedtoxicity.3. Acute Myeloid Leukemiaa. Molecular Makeup of Indian Patientsi. AYA (Adolescent and Young Adults) vs. Elderly Patientsb. Induction Mortalityi. Predicting Factorsii. Role of micro-transplantation in reducing InductionMortality4. Cancer Survivorshipa. Quality of Lifeb. Metabolic Syndromec. Cardiovascular side effects

118 NMR 118 (a) M.Sc.-Physical/Chemical/Biological/Life Science

Research Interests: Functional MRI, MRS, Cognition;Project: Morphological, functional, Biochemical andBehavioral evaluation post-EMF radiation (electromagneticradiation from mobile handsets)., Funded by SERB-DST,Govt. IndiaRs. 52,57,000.00Duration: 10.06.2015 to 09.06.2018

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

13

NMR 118 (b) M..Sc.-Physical/Chemical/Biological/Life Science with 2 yrs.Research Exp. Or B.Phrmwith 2 yrs. Exp./M.Phrm.

Project title: NMR phytometabolomics and studies ofchemosensory signature to address the fundamentalquestion of rasa of medicinal plants in ayurveda

There has been a resurgence of interest in phytochemicalresearch not only for identifying novel lead therapeuticcompounds but also for understanding how traditionalsystems of medicine use plants. Ayurveda has not only along history of usage of plants for medicinal purposes butinterestingly has its own pharmacological parameters todefine the therapeutic attributes of plants. A majorparameter in ayurvedic pharmacology is chemosensoryproperty of taste, known to modern chemistry as anorganoleptic property. Modern science has brought in itswake a number of analytical tools for research in medicinalplants. It is imperative for ayurveda to take advantage ofsuch tools to understand its knowledge base and add ontoit.

Much of the current research on medicinal plants inayurveda involves phytochemical and pharmacologicalanalyses to identify and isolate active principles.Considering that plants are used in their native form inayurveda, there is an inevitable necessity to evaluatemedicinal plants in terms of ayurvedic pharmacologicalparameters. Moreover, there is demand for quality controland standardisation of ayurvedic plants and medicines,which has also created a pressing need for appropriatemethodologies for comprehensive characterisation of plantsbeyond molecules. It is in this context that objectivemeasurement of ayurvedic pharmacological propertiesassumes importance.

Methodologies like differential sensing and spectroscopictechniques like Nuclear Magnetic Resonance (NMR) can beused to study plants as a whole without subjecting them toany preparatory procedures. This project is an exploratoryeffort, the first of its kind in literature, to study medicinalplants using NMR phytometabolomics from the perspectiveof ayurvedic pharmacology. The study will be an importantstep towards scientific understanding of ayurvedicclassification of plants in terms of modern terminologies.The major objective is to use NMR phytometabolomics forchemosensory signature of ayurvedic medicinal plants.

119 Neurology 119 (a) MBBS-1Bachelor of Engineering

Computer Science/ Masterof Physiotheraphy-1

I am presently working as Professor in the Department ofNeurology. Presently I am working on Epilepsy sourcelocalization and Sleep and cognition. The funding source isavailable for N-1438 and N-1557.

Neurology 119 (b) MBBS/MD (Medicine orCommunity Medicine)

The area of interest in Neuroepidemiology and the on-goingproject is under the principal Investigatror, Prof. KameshwarPrasad. I am a co-investigator in the project and havetraining in clinical epidemiology. I play to train the Ph.Dstudent in a topic. Pertainent to the data we are collecting incommunity dwelling participants 50 years of age and lookingat risk factors for stroke and dementia.

120 Clinical NeuroPsychology

120 (a) Master in Psychology I have been involved in research and clinical work since1987 and have been trained in NeuropsychologicalAssessment and Cognitive retraining/rehabilitation, ClinicalPsychological Testing, Personality Assessment and AptitudeTests, Teaching (Introductory and Applied Psychology;Developmental and Clinical Psychology),neuropsychological assessment, Lobar FunctionAssessment, Assessment of Disability, fitness and Cognitivereorganization/retraining of neurology and neurosurgerypatients (Manual and Computer based). Hence, my mainarea of interest lies in Neuropsychological assessment andrehabilitation with keen interest in developing tests andrehabilitation modules for varied conditions.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

14

Numerous neuropsychological tests and assessment toolshave been developed by the Clinical Neuropsychology Unitfor tapping onto the early assessment and diagnosis ofneurological conditions involving cognitive decline andscreening out neuropsychological impairment in order tochart out an early preventive treatment course by theclinicians. Several screening tests have been developedincluding the Dementia Assessment by Rapid Test (DART),which assesses cognitive decline for elderly population;Neuropsychological Evaluation Screening Tool (NEST),which screens out cognitive decline in various neurologicalconditions; and Preliminary Aphasia Screening Tool (PAST),which screen persons with language difficulty.

121 Neuro Surgery 121 (a) Master of PhysiotherapyB. Tech./BE in Computer Science/Master of Biotechnology

1. First post- Cognitive & physical Rehabilitation in epilepsysurgery2. Second post- EEG, magnetoencephalography and brainmapping for epilepsy

122 Orthopedics 122 (a) Master in Physiotherapy The subject will be randomized to exercise group providingproprioceptive exercise for “6” months or a control groupwhich will not participated in the structured exerciseprotocol.The balance analysis of static and dyanamic balance will beobjectively measured through balance master; analysis ofbrain waves will be done via EEG,Performance orientedmobility assessment scale, Timd up and go test, andincidence of fall will be measured at baseline, at 3 months, 6months and at 1 year.The incidence of fall in all the patients will be recorded.Sample size will be calculated in consultation with statistionwith effect size equal to anticipated reduction in theincidence of fall with intervention.

123 OcularPharmacology

123 (a) M.Sc. (Life Science) Research areas of the faculty members involve exploringthe functional importance of transporter proteins in ocularblood barriers in different ocular pathological conditionssuch as diabetic retinopathy, uveitis etc. In addition, pre-clinical studies and development of pharmacological agentsfor sex steroid deficient dry eye and retinalneovascularization are the other areas of interest.The following projects are ongoing at present which areactive in status and few of them will be getting extension:a. Evaluation of pharmacological interventions targetingretinal angiotensin system in retinopathy of prematurityfunded by DST.(Project code- D363)b. Collaborative Studies on Developing NewerAntimicrobials Based on QSPR Platform for its ProjectedUse in Ocular and other Infections by Vyome BioSciencesPvt. Ltd.(Project code- N1494)c. Invivo Based QSPR model for the In-Silico Prediction ofDrugs Penetrating Through Blood Retinal Barriers for High-Throughput Ocular Drug Development by DBT.(Projectcode-1593)d. Development and evaluation of longer storage cornealpreservation media & continuing the supply of cornealstorage media to Indian eye banks by MHFW.(Project code-56/Project/RPC)

OcularPharmacology

123 (b) M.Sc. (Life Science) Research areas of the faculty members involve exploringthe functional importance of transporter proteins in ocularblood barriers in different ocular pathological conditionssuch as diabetic retinopathy, uveitis etc. In addition, pre-clinical studies and development of pharmacological agentsfor sex steroid deficient dry eye and retinalneovascularization are the other areas of interest.The following projects are ongoing at present which areactive in status and few of them will be getting extension:a. Evaluation of pharmacological interventions targeting`retinal angiotensin system in retinopathy of prematurityfunded by DST.(Project code- D363)b. Collaborative Studies on Developing NewerAntimicrobials Based on QSPR Platform for its ProjectedUse in Ocular and other Infections by Vyome BioSciencesPvt. Ltd.(Project code- N1494)

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

15

c. Invivo Based QSPR model for the In-Silico Prediction ofDrugs Penetrating Through Blood Retinal Barriers for High-Throughput Ocular Drug Development by DBT.(Projectcode-1593)d. Development and evaluation of longer storage cornealpreservation media & continuing the supply of cornealstorage media to Indian eye banks by MHFW.(Project code-56/Project/RPC)

124 Ophthalmology 124 (a) M.Sc. (Optometry/Biotechnology/ Biosciences/Life Sciences

1. To evaluate the safety and effectiveness of thebioengineered corneas in a population of patientswith BCVA of 20/20 or worse due to cornealopacification from corneal injury or from stableKeratoconus.

2. Project title: Clinical study to evaluate thesafety and efficacy of the bioengineered corneain patients requiring deep anterior lamellarKeratoplasty.

Project code- 92/project/2016/RPC Duration-August 2016 to July 2017

3. To determine the specific microorganism causinginfectious Keratitis in Asian countries, and thefrequency and severity of these infections and riskfactors for infectious Keratitis in asian countries,including the role of contact lens wear. Todetermine the efficacy of current medical andsurgical treatment of infectious Keratitis in asiancountries and risk factors for poor visual outcomes.To establish a central repository of bacterial andfungal organisms cultured from asian patients withinfectious Keratitis for usae in future studies onmicrobial resistance and development of newtherapeutics.

4. Project title: Asia Cornea Society InfectiousKeratitis Study

Project code: 89/project/2016/RPC Duration:January 2016 to Oct 2017

5. PCR based detection of HSV-1 in suspectedherpetic Keratitis patients undergoing keratoplasty.Viral gene quantification by mRNA based analysisand real- time PCR and confirmation bysequencing, Immune-histochemical correlation ofthe cases for reviewing graft success/ failure.

6. Project title: Detection of HSV-1 etiology inprimary keratoplasty and failed grafts insuspected viral Keratitis cases: A prospectiveclinicopathological and molecular study.

Project code- I-846

Duration: Oct 2013 to June 2017

Ophthalmology 124 (b) M.Sc. (Optometry &Ophthalmic Technology/Biophysics/Biotechnology/Biochemistry/Life Sciences

Project Title: Safety and Efficacy of the Presbyopic IPCL forcorrection of Presbyopia with Moderate Myopia &Hyperopia: Prospective Clinical TrialThe study objective is to assess the safety and efficacy ofIPCL to correct presbyopia with moderate myopia orhypermetropia (with or without astigmatism). Preoperativeand postoperative detailed ocular examination includinguncorrected and corrected visual acuity, intraocularpressure, anterior segment evaluation, ASOCT for lens

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

16

thickness, glare acuity, orbscan, specular microscopy,fundus examination and macular OCT will be done.Preoperative Nd:YAG peripheral iridotomy will be performedin all cases. IPCL will be implanted in twenty patientsbetween 40-55 years old with stable refractive error between-5.0 to +5.0 D S and maximum 4.0 D of manifest refractivecylinder. Patients with anterior Chamber depth < 2.8 mm,endothelial cell density less than 2000 cells / mm3, one-eyed, pregnant, lactating or with other ocular or systemic co-morbidities will be excluded from the study. PostoperativeASOCT will be performed to assess IPCL vault and allcases will be followed up for three years..

Ophthalmology 124 ( c ) M.Sc. in Optometry/Ophthalmology

TOPIC: - Patterns of glaucoma progression in retinal nervefiber and macular ganglion cell-inner plexiform layer inspectral-domain optical coherence tomography withcomparison of Normal.PURPOSE:To evaluate the progressive changes of circumpapillaryretinal nerve fiber layer (RNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses measured byspectral-domain optical coherence tomography(HEIDELBURG SD-OCT) in EARLY GLAUCOMA ANDNORMATIVE INDIAN POPULATIONTo compare the glaucomatous patients and normalpopulation on Optical Coherence Tomography and SpectralConfocal Laser Scanning Ophthalmosopy on the basis ofoptic nerve head and retinal nerve fibre analysis. Earlydiagnosis and treatment of glaucoma is important to reducethe risk of progressive and irreversible visual loss. The keyto diagnosis is recognition of morphological changes to theoptic nerve head and retinal nerve fiber layer, but in somepatients, functional abnormalities are detected first. Thisreview describes recent innovations with the potential toimprove the early detection of glaucoma. Developments inimaging include novel optic nerve head metrics such asBruch's membrane opening-minimum rim width, enhancedability to quantify inner layers of the glaucomatous macula,and ability to image deep optic nerve head structures,including the lamina cribrosa. Developments in detection ofearly glaucomatous functional loss include novel perimetrictests Methods to combine results of structural and functionalassessments are also presented that may improve earlydetection of glaucoma.

125 Obst. & Gynae. 125 (a) M.Sc. inBiomedical Sciences/Biochemistry

Brief write up (300 words) about his research interest andon-going projects with funds, fellowship and duration.Dr. J B Sharma is a Professor of Obstetrics andGynaecology at All India Institute of Medical Sciences, NewDelhi. He is a Fellow of the Royal College of Obstetricians &Gynaecologists, London, National Academy of MedicalSciences, New Delhi and International Academy of MedicalSciences and of FOGSI. He is interested in research andhas completed two research projects entitled “CORONIS:International Study of caesarean Section Surgical technique,A randomised factorial trial” and “Caesarean section surgicaltechniques: 3 year follow-up of the CORONIS fractional,factorial, unmasked, randomised controlled trial,” funded byNPEU, University of Oxford with two papers published in the‘Lancet’. He has already completed research project entitled“A Study on Treatment of Genital Tuberculosis: ARandomized Controlled Trial of Either Discontinuation at 6Months or Continuation Till 9 Months After Initial Responseto 6 Months RNTCP Category 1 Treatment.” with Central TBDivision, Ministry of Health and Family Welfare, Govt. ofIndia. The same has been published in European Journal ofObstetrics and Gynaecology and Reproductive Biology. Hehas another on-going research project with ICMR entitled“Effect of Non-ionizing Electro Magnetic Field (EMF) onHuman Health”.He has been granted research project entitled “Evaluation ofGene expert as compared to conventional methods indiagnosis of genital TB among infertile women,” with Central

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

17

TB Division, Ministry of Health and Family Welfare, Govt. ofIndia for a period of 3 years with one post of Senior researchFellow, one Data Entry Operator and one Attendant.Hence, it is planned that a PhD student can be taken underthe project for which salary can be paid from the project.

7. Please indicate source of funding for the proposed Ph.D.student and a detailed plan for sustaining the Ph.D. studentfor his tenure along with the code no. of research projectwith duration of project.Dr. J B Sharma has got funding from Central TB Division,Ministry of Health and Family Welfare, Govt. of India on aresearch project entitled “Evaluation of Gene expert ascompared to conventional method in diagnosis of genital TBamong infertile women” for a period of 3 years. Firstinstallment has already been provided to research Section,AIIMS, New Delhi vide project code no: N-1680. Gene XpertMTB/RIF is an automated nucleic acid amplification test fordetection of tuberculosis and rifampin resistance forpulmonary and extra pulmonary tuberculosis.It is proposed to conduct a study on Gene Xpert SensitivityMTB/RIF in diagnosing female genital tuberculosis andassessing the Performance of Xpert MTB/RIF culturemethod with other traditional methods like AFB culture,PCR, radiological imaging, laparoscopy and hysteroscopy.The sensitivity and specificity of Gene Xpert will becompared and contrasted with traditional method (PCR,AFB culture and histopathology findings).It is planned that the PhD student can be taken and can getthe salary from the project for 3 years

126 Pharmacology 126 (a) MBBS/BDS/M.Sc. in Pharmacology/BAMS/MD (Pharmacology)

Project entitled “Anti-inflammatory strategy in the treatmentof Pulmonary Artery Hypertension.” has been approved andfunded by ICMR . Study has been approved fromInstitutional Animal Ethics Committee.Objectives is to study monocrotaline (MCT) – induced modelof pulmonary artery hypertension in rats in respect toinflammation as a etiopathological factor. And to evaluatethe effect of a Lipoprotien Associated Phospholipase A2(LpPLA2) inhibitor (Darapladib) in MCT-induced pulmonaryartery hypertension in rats. Also to evaluate the effect of aPPAR-α Agonist in MCT induced pulmonary arteryhypertension in rats.

Pharmacology 126 (b) M.Sc. (Life Science)/M.Sc. (Pharmacology)/Master of Pharmacy

Actively involved in research in the field ofneuropharmacology, Area of interest is epilepsy and pain.Published research papers and medical reviews ininternational and national journals of repute like BritishJournal of Parmacology, Envionmental Toxicology andPharmacology, Methods and Findings in Experimental andClinical Pharmacology , Neurobiology, International Journalof Neurosciences, Neurosciences Letters, EpilepsyBehaviour etc. Currently, we are working on elucidating theRole of Neurogenesis inhibitors in preventingepileptogenesis, biomarkers for predicting at risk populationfor Sudden Unexpected death in epilepsy (SUDEP),depression as a comorbid condition in persons with epilepsyetc. Ongoing projects –

• “To determine the relationship between seizures andcardiac remodeling in lithium-pilocarpine model in rats –Effect of AT1 receptor blocker losartan and selective betareceptor antagonist atenolol”, funded by AIIMS, New Delhi.

Duration – 2 yearsFunds – 5,30,000/-

• “Role of Brain derived neurotrophic factor (BDNF) as abiomarker in seizure related cardiac abnormalities.”, fundedby Department of Science and Technology.Duration - 2 yearsFunds – 21,35,280/-Fellowship – 1

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

189

Pharmacology 126 (c) M.Sc. (Pharmacology)/M. Pharmacy/MBBS/BDS

With increasing treatment options, improving diagnosticsand enhancing role of genomics and proteomics,personalized medicine is the need of the day. We areworking in the field of clinical pharmacology with emphasison oncology and cardiology. Our current work is on the roleof certain molecular chaperone in response to therapy inmultiple myeloma patients. We are also working on role ofgene polymorphisms and trace elements in cancers. Wehave intramural and extramural funding and work is inprogress in setting up a molecular lab with estimation ofdrug concentrations.

Pharmacology 126 (d) M..Sc.-Pharmacology Research Interest: Ischemia reperfusion

Project with funds, fellowship and duration

Title of the project: “Studies of the mechanism involved incardio-protective effect of Dipeptidyl peptidase-4 inhibitor,saxagliptin in ischemia- reperfusion model of myocardialinfraction in streptozotocin induced diabetic rats”Code No.: N-1645Research Interest: Network program on SeabuckthronProject with funds, fellowship and durationTitle of the project: “Development of herbal formulation fromseabuckthron, Molecular and Pharmacological investigation onefficacy of combination of seabuckthron oil and ramipril vis-à-visramipril alone in experimental models of myocardial infraction instreptozotocin-induced diabetic rats”Code No.: BT-1723

Pharmacology 126 (e) M.Sc.-Pharmacology Research Interest: Nephrotoxicity, PulmonaryPharmacologyProject with funds, fellowship and durationTitle of the project: “Evaluation of the nephroprotectiveeffect of berberine and diadzein in cisplatin inducednephrotoxicity in rats”Code No.: N-1606Cisplatin is widely used anti-cancer drug but its use islimited by side effects such as nephrotoxicity. Oxidativestress and inflammation plays an important role in thepathogenesis of cisplatin-induced nephrotoxicity. Berberineand diadzine have shown to demonstrate antioxidant, anti-inflammatory, hepatoprotective, renoprotective and anti-apoptotic activities. But their effect has not beendemonstrated so far in cisplatin induced nephrotoxicity.Based on this background, present study was designed toevaluate the protective role of berberine and daidzein incisplatin-induced nephrotoxicity in rats.

127 Physiology 127 (a) M. Biotechnology My current research is based on sleep.

Physiology 127 (b) M.Sc. (Life Science) I am presently working as Professor in the Department ofPhysiology. Presently I am working on Cellullar & Molecular

Physiology. The funding source of my research is DSTProject no. D 368 with a post of Research Assistant.

Physiology 127 (c) M.Sc. (Life Science/Human Physiology/Yoga/Rehabilitation

Rresearch interest is Neurophysiology of brain stimulationand the group is working on pathogenesis of chronic painand the central and peripheral factors involved in its

modulation and relief. Effect of repetitive Transcranialmagnetic stimulaion and other non invasive means ofchronic pain management are being explored at painresearch and TMS lab, convergence block. The currentproject is aimed at understanding the pain status andcortico-motor excitability using TMS in chronic low backachepatients and also to explore the role of yoga in the same .Already enrolled students have their own fellowships (UGC)and current request is for a PhD for SATYAM (DST)

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

19

approved project for 3 years (2017-2020)

Physiology 127 (d) M.Sc. (Physiology/Neuroscience/Life Sciences/Zoology/MBBS/BDS

1.Title: QEEG based neural correlates and microstatesof attention and interference in ADHD: Anendophenotypic marker

ADHD is a common neurobehavioral disorder of childhoodboth in developed and developing countries. It can presentas impaired attention, excessive motor activity, impulsivityand may progress till adulthood. The risk of ADHD to first-degree relatives is around four to ten times compared to thegeneral population.Thus, it is critical to explore and assessan endophenotypic marker, which if present in first degreerelatives can help to develop early diagnosis and treatmentstrategies.

Also, there have been controversies regarding diagnosisand treatment of the ADHD. An accurate diagnosis guideseffective treatment. But, ADHD is diagnosed based onclinical interview, which delays initiation and maintenance oftreatment. Thus, need of the hour is to establish thealterations in neural circuitry in ADHD with the help of EEG,both at rest and during activation in response to cognitive oremotive challenge (important in day to day living). Selectiveattention is the most affected domain. Only visual attentiontasks have been documented but it is necessary tounderstand what the changes are during auditory selectiveattention as well. Further, inhibition of selective attentionduring certain environmental conditions is essential forsurvival. This can be best studied using interference tasks(emotional and non- emotional).Therefore, we aim to assesscognitive and quantitative EEG changes at baseline andduring attention and interference tasks in ADHD patients ascompared to first degree relatives and controls. Also, anattempt will be made to develop quantitative EEG basedneural correlates and microstates as an endophenotypicmarker in ADHD.

2.Title: Study of brain iron levels and cortical sources ofEEG during visuospatial working memory in AttentionDeficit Hyperactivity disorder

This project is aimed to assess the role of iron in implicationof ADHD. In Indian subcontinent, ADHD is reportedsignificantly more commonly in children belonging to a lowersocioeconomic status, stress and malnutrition being themost hypothesized risk factors leading to ADHD. Toelucidate the same, brain iron and salivary ferritin will betaken as markers of nutrition and QEEG changes, salivarycortisol and amylase will be taken as markers of stress.

Modern neuroimaging techniques have revolutionized ourknowledge about neural mechanisms of various psychiatricdisorders including ADHD.Recent study by Adisetiyoetal(2014)has documented the use of brain iron as abiomarker in patients with ADHD, who respond topsychostimulant therapy.Brain iron is regarded as apotential dopamine-related biomarker because (a) it is arequired cofactor for dopamine synthesis (Daubner et al,2011) (b) altered iron levels have been associated withcognitive and dopaminergic changes and (Beard et al,2003)(c), in contrast to the radioactive tracers used as dopaminebiomarkers in molecular imaging, brain iron can be probed

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

201

noninvasively with the use of magnetic

resonance (MR) imaging methods (Dusek etal,2013)Cortical activity can also be studied usingquantitative EEG. QEEG provides excellent temporalresolution and with the aid of 128 channels, better spatialresolution too.No Quantitative EEG studies are available (tothe best of our knowledge) assessing brain activity duringvisuospatial working memory task in ADHD. Also, sourceanalysis will help us in understanding the underlying neuralgenerators.

Further, it is imperative to know whether there is acorrelation betweensourcesactivated/deactivated duringEEG and brain iron levels (which is reported to decrease inADHD). This can help us identify the biomarker for ADHDeither in terms of brain iron (as assessed by MRI) or corticalsources especially during visuospatial working memory.

128 Psychiatry 128 (a) M.Sc. (Biochemistry/Pharmacology/Organic Chemistry/Biotechnology/Forensic Science

Project entitled: “Role of Delphinium denudatum (Jadwar) ina Rat Model of Nicotine Dependence”

SummaryTobacco use is the leading cause of preventable death inthe World. It is the largest single cause of premature deathin developed countries, and about half of those who smokefrom adolescence throughout life will die from smokingrelated diseases. Nicotine, the main psychoactiveingredients of tobacco contributes to the harmful tobaccouse. Chronic administration of nicotine produces toleranceand dependence in both humans and animals. Quittingtobacco greatly reduces the risk of developing tobacco-related diseases. The optimal approach to pharmacologicaltherapy for successful smoking cessation has not been fullyunderstood. Till date, there is no published report toexamine the effect of Delphinium denudatum root extract aswell as on Unani formulation of Delphinium denudatum(Habb-e Jawahar) on animal model of nicotine dependence.Recent research reports on animals suggest, role ofDelphinium denudatum (Jadwar) in suppression ofmorphine withdrawal. Based on these findings, it ishypothesized that aqueous/ethanolic extract of Unaniformulation of Jadwar (Habb Jawahar) and ethanolicextract of Delphinium denudatum roots may attenuatenicotine withdrawal due to common neurobiologicalmechanisms for dependence. Also, the findings of theproposed study would provide further insight to understandthe neurobiological mechanisms of nicotine dependence. Ifthis proves to be effective, it can be used as acomplementary therapy for smoking cessation in the Indiancontext to deal with the problem of tobacco dependenceProject entitled: “Role of Delphinium denudatum (Jadwar) ina Rat Model of Nicotine Dependence”SummaryTobacco use is the leading cause of preventable death in

the World. It is the largest single cause of premature deathin developed countries, and about half of those who smokefrom adolescence throughout life will die from smokingrelated diseases. Nicotine, the main psychoactiveingredients of tobacco contributes to the harmful tobaccouse. Chronic administration of nicotine produces tolerance

and dependence in both humans and animals. Quittingtobacco greatly reduces the risk of developing tobacco-related diseases. The optimal approach to pharmacologicaltherapy for successful smoking cessation has not been fullyunderstood. Till date, there is no published report toexamine the effect of Delphinium denudatum root extract as

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

21

well as on Unani formulation of Delphinium denudatum(Habb-e Jawahar) on animal model of nicotine dependence.Recent research reports on animals suggest, role ofDelphinium denudatum (Jadwar) in suppression ofmorphine withdrawal. Based on these findings, it ishypothesized that aqueous/ethanolic extract of Unaniformulation of Jadwar (Habb Jawahar) and ethanolicextract of Delphinium denudatum roots may attenuatenicotine withdrawal due to common neurobiologicalmechanisms for dependence. Also, the findings of theproposed study would provide further insight to understandthe neurobiological mechanisms of nicotine dependence. Ifthis proves to be effective, it can be used as acomplementary therapy for smoking cessation in the Indiancontext to deal with the problem of tobacco dependenceProject entitled: “Role of Delphinium denudatum (Jadwar) ina Rat Model of Nicotine Dependence”SummaryTobacco use is the leading cause of preventable death inthe World. It is the largest single cause of premature deathin developed countries, and about half of those who smokefrom adolescence throughout life will die from smokingrelated diseases. Nicotine, the main psychoactiveingredients of tobacco contributes to the harmful tobaccouse. Chronic administration of nicotine produces toleranceand dependence in both humans and animals. Quittingtobacco greatly reduces the risk of developing tobacco-related diseases. The optimal approach to pharmacologicaltherapy for successful smoking cessation has not been fullyunderstood. Till date, there is no published report toexamine the effect of Delphinium denudatum root extract aswell as on Unani formulation of Delphinium denudatum(Habb-e Jawahar) on animal model of nicotine dependence.Recent research reports on animals suggest, role ofDelphinium denudatum (Jadwar) in suppression ofmorphine withdrawal. Based on these findings, it ishypothesized that aqueous/ethanolic extract of Unaniformulation of Jadwar (Habb Jawahar) and ethanolicextract of Delphinium denudatum roots may attenuatenicotine withdrawal due to common neurobiologicalmechanisms for dependence. Also, the findings of theproposed study would provide further insight to understandthe neurobiological mechanisms of nicotine dependence. Ifthis proves to be effective, it can be used as acomplementary therapy for smoking cessation in the Indiancontext to deal with the problem of tobacco dependence

Psychiatry 128 (b) Master Degree/M. Phil in Psychology/Clinical Psychology

Effects of multimedia intervention (diet, exercise andcomputer based cognitive training) in comparison to healthawareness amongst elderly subjects from varioussocioeconomic clusters with subjective memory complaints.

Psychiatry 128 (c) Master Degree inPsychology/M. Phil in Psychology/Clinical Psychology

Development of cognitive retraining module for improvingcognitive deficits of abstinent patient with alchohaldependence syndrome, cannabis dependence syndromeand opioid dependence syndrome in a tertiary care de-addiction centre of Northern India

129 Pathology 129 (a) M.Sc. (Life Sciences) Breast Cancer:• There has been a global surge in incidence of breastcancer in young females. I have an ongoing project in which

we are doing Stratification of breast cancer in young femalesby molecular subtypes and androgen receptor status. Themolecular subtypes will be correlated with pathological andsurvival parameters.• I have a sanctioned extramural project on evaluation of

prognostic role of tumour infiltrating lymphocytes and PDL!In Breast Cancer• The heterogenic nature of breast carcinomas and diversepatterns of growth and invasiveness emphasize the need forprognostic and predictive biological markers for aggressivetumors. I was part of Indo-Canadian collaborative study to

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

223

evaluate the prognostic utility of Ep-ICD by characterizingthe subcellular expression of Ep-ICD and EpEx in breastcarcinomas using immunohistochemistry and correlatingwith clinicopathological parameters and the follow up ofpatients to investigate its potential to predict aggressivetumors that may aid in the management of breast cancerpatients.• A novel method of performing FISH for her-2 neu on airdried archival stained smears has been developed. Usingthis technique FISH can be performed on even old archivedsmears.• In a collaborative project with public health foundation ofIndia we are evaluating reproductive, lifestyle, genetic and‘life course’ risk factors associated with breast cancer (BC)tumour sub-types and stage of disease; the associationbetween risk factors and mammographic density (MD); andto set up a platform for evaluating BC survival, all of whichare important for BC prevention and control in India.• I also have collaborative projects with dept ofRadiodiagnosis, surgery, surgical oncology & biochemistryfor enhancing diagnosis & management of breast cancer.These have culminated in some excellent publications whichhave made valuable inputs to world literature on this subject

Gynaecologic Cancers• In the field of cervical cancer much needed benchmarkpublications in Indian context have been generated thathave provided insight into HPV type distribution, accuracy ofvarious screening modalities, utilization of novel techniquesfor screening, crucial biomarkers to be studied etc. This hasoverhauled the way in which cervical cancer is screenedand diagnosed in various clinical settings in India.

• I have recently completed research work on neoadjuvantchemotherapy induced alterations of prognostic markers inserous ovarian carcinoma which has given some importantinsights on the survival of ovarian cancer.

• Efforts are ongoing to develop the use of biomarkers indifferentiating endometrial hyperplasias from carcinomasand the pathway of endometrial carcinogenesis, in order toimprove diagnosis & understanding biology of thismalignancy.

Pathology 129 (b) M.Sc. (Life Sciences) I am actively involved in clinically oriented and basicresearch in the field of Neuro-oncology. My primary work isrelated to development of comprehensive approaches tounderstand the biology of CNS tumors with specialreference to gliomas , meningiomas and medulloblastomasand to develop markers that could help their early diagnosisand prognostication. With this aim, I have studied bothpediatric and adult CNS tumors extensively.

Pathology 129 (c ) M..Sc.(Biotechnology/Microbiology/Life Science)

The National Cancer Registry Programme (NCRP) data

published by ICMR bulletin in 2010 stated an

approximate of 4-5% annual percentage increase in

incidence of CRC in Chennai and Bangalore, while in

Delhi the annual increase of incidence documented was

1.7%. Though in India overall prevalence of CRC is low,

lack of health awareness leads to disease being

detected at an advanced stage, resulting in dismal

overall 5 year survival even with treatment.As a measure

to check rise of annual incidence, there is need to

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

234

establish a population based CRC screening programme

targeting the high-risk subjects with an aim to identify

mucosal carcinogenesis at an earlier stage. With the

currently available colonoscopic screening, at the best

we can identify elevated mucosal pre-neoplastic lesions;

however, when detected many complex genomic

alterations already have taken place in them. On the

other hand, tiny microscopic pre-neoplastic mucosal

lesions known as aberrant crypt foci (ACF), have been

found as the earliest mucosal pre-neoplastic lesion,

identifiable in-vivo by magnified chromoendoscopes. In

this DBT funded project we are trying to define

phenotypic and genotypic characteristics of ACF like

lesions in human colon. We have standardized protocol

of detection of such lesions, which mimic

chromoendoscopic detection. For genotypic analysis we

are selectively sampling these lesions post-detection and

extracting DNA and RNA. Total RNA is being used for

quantitative PCR analysis for various genes which are

known to participate in colorectal carcinogenesis,

including pro-oncogenes, genes regulating mucosal

inflammation, etc. The DNA extracted is being used for

methylation analysis of selected known tumor

suppressor genes. After completion mRNA expression

profiles would be matched with their methylation

phenotype, as well as with different topographic ACF

types, location of ACF (right versus lest), histological

findings, etc. We also would validate the gene

expression profiles identified by qPCR analysis. Exact

characterization of these potential microscopic lesions is

necessary before they can be advocated for

chromoendoscopic screening, which we are aiming at.

130 Pediatrics 130 (a) M.Sc. (Human Genetics/Life Sciences

Intellectual disabilities, inborn error of metabolism skeletaldysplasia

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

24

Pediatrics 130 (b) M.Sc. (Biotechnology/Biochemistry/Zoology)

Acute lymphoblastic leukemia & acute myeloid leukemia(understanding mechanisms of poor response andassessment of minimal residual disease) Indian childhoodleukemia collaborative group (ICiCle) ICMR & NCG fundedmulticenter study Cancer survivor ship & late effects Inaianpediatric oncology group multicenter study C2S study:Childhood cancer survivorship study Histiocytosis & Hodgkinlymphoma & role of biomarkers in infections are other areason interest.

Pediatrics 130 (c) M.Sc. Life Sciences/Biotechnology)

The division of pediatric nepohrology is involved in research onneprotic syndrome, glomerulonephritis and haemolytic uremicsyndrome. Through funding from DBT, ICMR, DST and otherfundig agencies the division is involved in prospective inprospective studies on the pathogenesis and outcome of thesedisorders.

Pediatrics 130 (d) M. Sc- (Home) Division of Genetics Department of Pediatrics has beenworking in the area of inborn errors of metabolism for a longtime and it is one of the major areas of interest. Dietarymanagement is an integral component of management ofthese disorders . There is a need for research in this area inIndia as the therapeutic diets are not manufactured locally .Candidate should be interested in the area of dietarymanagement of Inborn Errors of Metabolism and mustcontribute significantly to research in this area.

Pediatrics 130 (e) M.Sc. (Life Sciences/Biotechnology/Biochemistry/Molecular Biology)

Research interests include pediatric endocrine disorders liketype 1 diabetes, disorders of sex development origins ofhealth and disease, optimal trajectory of growth and bodycomposition in low weight infants, and obesity and metabolicsyndrome in children and adolescents.

131 ReproductiveBiology

131 (a) M.Sc. Reproductive Biology/Biotechnology/ Biochemistry/Life Sciences.

To elucidate epigenetic regulation during reproductive agingusing C. elegant as model system. Advanced maternalreproductive age is known to influence the process of oocytematuration and embryonic development. Children born to anolder mother are prone to the onset of one or other form ofthe diseases in the adulthood. Recently it has become clearthat the epigenetic modifications are not only involved inwell-established biological processes such as dosagecompensation and genomic imprinting but also ingametogenesis and embryo development. Epigenomicprofiling has served to better define critical DNA controlelements, such as gene enhancers and promoters. Whencombined with DNA sequence, it can provide insights intovarious disease processes and progression. Further, theseepigenetic modifications are dynamic and reversible,offering considerable promise for therapies drawing upontheir adaptive nature. It makes epigenetic studies inreproductive aging as one of the most innovative researchareas in modern biology and medicine. These observationsprompted us to decipher the correlation of global geneexpression with epigenetic modifications in older oocyte/embryo that may lead to an unhealthy adult organism. Therecurring theme of this work is to elucidate the genome widemolecular mechanism that controls the reproductive healthof the mother and the complexities that arise in the offspring.In our work, we would like to perform chromatinImmunoprecipitation (ChIP) combined with massive parallelnext generation sequencing (ChIP-seq), whole genomemicroRNA and RNA sequencing that has empowered us todevelop the precise association of global gene expressionwith epigenetic profiling at or near base pair resolution inboth normal and abnormal cells and tissues. This workintends to understand the transcriptional relevance withepigenetic profiling during reproductive aging usingCaenorhabditis elegans as a model system. This worm hasemerged as an outstanding model system to study thebiology of reproductive aging primarily due to its short andreproducible life span, well demarcated developmentalstages, transparent body with easy identification of gonadalcells, high fecundity, conserved genes, low maintenancecost and amenability to high-throughput techniques.Ongoing Project: Under Fund transfer process by SERB-DST (expected in a month or two)

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

256

ReproductiveBiology

131 (b) M.Sc.(Reproductive Biology/Biotechnology/Biochemistry/Life Sciences

Research area of Interest area) Molecular and Biochemical aspects of Leydig cellsteroidogenesis,b)effect of endocrine disrupter on Sperm functions.c)Sperm cryo preservation,d)efficacy of herbal drugs/extracts on prostate cancer celllines and Leydig cell steroidogenesis.One JRF/SRF position is available in project Quality controlfor hCG kits. This project is ongoing continuous project forquality controls testing of PTK kits.

ReproductiveBiology

131 (c ) M..Sc.(Rep. Biology/Biotechnology/Biochemistry/Life Sciences or MBBS orM.Vsc

Research interest include:a) Molecules involved in mammalian sperm-egg fusionb) role of MicroRNAs in moduling functions of trophoblastcells of the placenta.Title:“Generation genome edited mice using CRISPR/Cas-9based knock-out/knock-in technology to study mammaliansperm-egg fusion”.

132 T.I.I. 132 (a) M.Sc. Immunology/Genetics/Biotechnology/Biochemistry/Life Sciences and MBBS,

MD (Pathology)/Biochemistry/Microbiology/Pharmacology)

I have been actively engaged in dissecting the role of cell-mediated immune responses in the pathogenesis of humanTuberculosis& Leishmaniasis. We had earlier demonstratedthat Treg cells are preferentially recruited at the pathologicsites of miliary tuberculosis and~75% of the patients withpersistent Treg cells finally progressed into Multi-DrugResistance(MDR) cases. These observations suggested animportant role of Treg cells in the development of MDR.Oneof the mechanisms of drug resistance inM. tuberculosis(Mtb)is increased drug efflux. However, the role of T cell inducedmacrophage function on the efflux pumps and thusemergence of DR strains of Mtb remains unclear. We areevaluating the impact of host T cell response on expressionand function of both bacterial and macrophage drug effluxpumps.In an ongoing study, we aimed at understanding the impactof Treg cells and negative costimulatorymolecules,PD-1/PD-L1 in shaping or influencing the fate of Mtb specificpolyfunctional T cells among latent and active tuberculosispatients. Understanding the differential impact of Treg cellsand PD-1 mediated suppression of Mtb specificpolyfunctional (TNF-α, IFN-γ and IL-2) T cells of tuberculosispatients is of profound importance for identifying potentialbiomarkers for breach of latency. Indeed, we have datashowing that blockingPD-1/PD-L1 interaction preferentiallyrescues polyfunctional effector T cells both in vitro and invivoMtb infection models. This possibly will reveal putativestrategies to modulate and maintain the optimally qualitativepolyfunctional T cells response. Data obtained from thisstudy may also help identify the signature immune responsewhich may serve as a correlating biomarker for assessingthe host immune response during disease progression andnew generation vaccine trials.In parallel, we are investigating the role of PD-1/PD-L1pathway towardssuppressed immune response inLeishmaniasis. There is a strongpossibility that parasiteinduced anergic effector cells express high levels of PD-1and ultimately suppress function. Over-expression of PD-1on effector T cells can be a major contributor to partialefficacy of vaccinecandidates and blocking PD-1 could leadto increased efficacy. We are also collaborating with ZYDUSCADILA towards development of a novel, safe andefficacious Leishmania Vaccine at affordable cost. We arecombining various parasite life cycle related proteins toblock its transmission and making a new formulation inimmuogenic Virosome form and further adjuvanted withGLA-SE (TLR 4 agonist) for the first time.

T.I.I. 132 (b) M.Sc. (Immunology/Genetics/Biotechnology/

Our group at the Centre for Molecular Medicine is focussedtowards developing newer technologies for improvinggenetic matching betweeen recipient-donors, improvisingimmunological and immunogenetic assays for organ and

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

26

Biochemistry/Life Sciences and MBBS,MD (Pathology)/Biochemistry,Microbiology,Pharmacology)

stem cell transplant monitoring (Anti-Donor antibody andchimerism testing), identifying markers to predict transplantoutcome, development of in-house assays forpharmacogenomic testing for drug hypersensitivity(Abacavir-HIV and Carbamezepine-Steven JohnsonSyndrome). Our group offers regular teaching/training intransplant immunology and runs a national qualityassurance program for HLA genotyping.Our grouphas been actively engaged in understanding thegenetic diversity of HLA genes in several Indian populationsand we have demonstrated presence of several rare/uniqueHLA alleles and haplotypes in both tribal and non tribalIndian populations. We have established multiple highresolution high throughput technologies to understand thegenetic diversity of HLA alleles. Recently, next generationsequencingtechnology has been established and is likely tobe implemeted for departmental research and patient careservices. The technology advancements have improved thedonor selection such that post transplant alloimmunoeresponses can beminimised. This also helps in identification of donor specificantibodies that are potential threats to allograft survival.Our studies on understanding the molecular basis ofdisease susceptibility have identified unique HLA alleles andhaplotypes associated with diseases like Type 1 Diabetes,Immune Thrombocyopenia Purpura and AnkylosingSpondylitis. We identified unique HLA-DR3+ve haplotypesassociated with T1D in North Indian, South Indian andKashmiri population. The haplotypes observed in Indianpopulation differ from the haplotypes associated with T1D inCaucasians.We are presently investigating the role of non-classical HLAgenes like HLA-G and HLA-E in organ and hematopoieticstem cell/bone marrow transplantation. We investigated thediversity of HLA-G and HLA-E in North Indian ppulation. Wealso studied the polymorphism in the 3’UTR region andoberved coorelation between the soluble HLA-G levels and3’UTR SNPs and haplotypes. Our studies on clinicalrelevance of HLA-G in hematopoietic stem cell/bone marrowtransplantation have demonstrated that the soluble HLA-Glevels are dependent on 3’UTR 14bp Insertion/deletion andUTR haplotypes of the recipent. Further, the serialmonitoring of pre and post transplant soluble HLA-G levelsappear to be useful in predicting the transplant outcome aslower soluble HLA-G levels corelated with episodes of graftversus host disease in HSCT and acute rejection in renaltransplants.Our studies on impact of HLA-G on host immune responsein human tuberulosis revealedthat expresssion of HLA-Gand its receptor ILT2 could differentiate between thelocalized versus disseminated TB. Further the leadsobserved indicate that determining the alterations in thelevels of sHLA-G post treatment (Anti-tubercular Therapy)might have added value in its use as a potential biomarker.In addition, HLA-G expression could serve as a correlatingbiomarker for assessing the host immune response duringTB progression and vaccine trials with new generationvaccines.

133 Lab Oncology 133 (a) M..Sc- Biotechnology/Life Science

“A prospective study to evaluate WT1 gene expression as

predictive molecular marker of disease progression in de

novo cases of Acute myeloid Leukemia”

Acute myeloid leukemia (AML) is group of hematological

malignancy. Treatment protocols for AML cases are

available. However, for the successful implementation of

treatment protocols close laboratory follow up for the

disease progression is required. Minimal residual disease

(MRD) is an important aspect to evaluate the quality of

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

27

response and predicting relapse rate in AML patients.

Several studies have shown the usefulness of various

modality such as multiparametric flow cytometry,

polymerase chain reaction and fluorescence in situ

hybridization for detection of MRD in AML patients. PCR-

based quantification of MRD has a high sensitivity but its

applicability is restricted to subgroups of AML with leukemia

specific molecular targets. Wilm’s tumor gene 1 (WT1)

expression can be found in 70 % to 90 % of patients with

acute leukemia (AL). However, there is paucity of data

regarding the normal expression level of WT1 in Indian

population and it effect on treatment response. In this study,

we will be evaluating the expression of WT1 with help

reverse quantitative polymerase chain reaction (RQPCR) in

all de novo cases of AML. WT1 expression values will be

compared with progression of disease to validate WT1 as

possible molecular marker in AML.

134 CommunityOphthalmology

134 ( a) MD/MS/DNB/Diploma in Ophthalmology/MD in Community Medicine/Master in OptometryOccupational therapy(regular) from recognizeduniversity

An Operational Research on Developing DisabilityInclusive Eye Health Program in India

Phase 1: Epidemiological study of visual impairment,including low vision and blindness in (Gorakhpur UPand Sehore MP) districts, Delhi India

Objectives:

1) To assess the prevalence and causes ofvisual impairment including low visionand blind

2) To assess the prevalence of operablecataract, refractive error, Presbyopiaamongst study sample

3) To identify the barriers in availing the eyecare services (especially Cataract andRefractive error)

An additional objectives in Delhi only

4) To assess the needs in terms ofhealthcare, social and rehabilitation ofblind and low vision patients

5) To map the available human resourcesand infrastructure for low vision andrehabilitation services

Study design: Population-based Epidemiological study onvisual impairment, low vision, and blindness in the selecteddistricts, and designing an eye care model accordingly

Sample size: Delhi (3000 which includes ≥5 years age),Gorakhpur UP, and Sehore MP (2000 aged 40 years andabove)

Sampling methodology: Multi-stage cluster randomsampling- one subdivision from selected district will be

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BATC

H 20

17PR

OSPE

CTUS

286

Note: A candidate is allowed to submit application for one speciality / subject only

3. GENERAL ELIGIBILITYEligibility for Ph. D course (Open candidates)

A candidate seeking admission to the course of study leading to the award of a Degree of Doctor ofPhilosophy must possess at least one of the following qualifications:

1. (a) Medical qualification: MBBS/BDS with minimum 55% aggregate marks or MD/MS/MDS/DM/MCh in the subject concerned or Diplomate of National Board of Examination.Candidates who have obtained any of these degrees from medical colleges which arenot recognized by the Medical Council of India shall not be eligible to apply.

(b) Nursing Qualification: Candidates holding M.Sc degree with minimum 55% aggregate marks inNursing Speciality will also be eligible for Ph. D admission in College of Nursing.

2. Non-Medical – For non-medical candidates eligibility shall be Master’s Degree (two years course)awarded by Indian Universities or equivalent in the subject as per requirement of the project.Candidates holding M.Sc. (Other than M.Sc. Nursing) M.Tech. degree & BAMS will be eligiblefor the Non-Medical Qualification Category.

chosen randomly. Further, random selection of 2blocks/wards will be done. In India, there are on average 60-100 villages in a block. With the help of PPS technique,villages will be selected from the chosen block. This willensure the selection of the higher number of villages in thesample from a block with a higher number of villages. Forinstance, if one block/ward has a higher number of villagesas compare to other, then more villages are likely to bechosen from the concerned block.

The selected villages will be divided into a number ofsegments of 100 to 200 populations. The selection ofhouseholds will be done with the help of compact segmenttechnique. Total 30 segments will be covered in the study(Delhi). From each segment, 100 individuals will beenumerated and examined. Whereas, Gorakhpur andSehore, 20 total segments will be covered in each.

Phase 2: Based on results of the first phase, to developa suitable model for disability (low vision and blind)inclusive eye care program in Delhi: A Pilot Model

Objectives: to develop a suitable and affordabledisability inclusive eye health care model

Model: Based on the results, a suitable program will bedesigned to cater problems of the population. Thefocus will be on the service for low vision and blindpatients. At the outset, the designed program will bepiloted in Delhi.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

29

Candidate possessing Masters Degree through distant learning course shall not be eligible

While seeking project details from the department, desired qualification of Masters Degree to besuitable for project work should be mentioned by the respective department. The same will bedisplayed along with Number of Seats & Department.

Candidate having eligibility under non-medical category should have at least 60% marks in the lasteligibility examination qualified.

Desired qualifications

The non-medical candidates should have preferably qualified in any one of the following nationalentrance tests in the last 2 years:

o Joint CSIR-UGC NET for JRFo ICMR – JRFo ICMR- SRFo DBT – JRFo DBT - SRFo NBHM screening testo Graduate aptitude test (GATE)o INSPIRE fellowshipo UGC – JRFo UGC - SRFo CSIR – JRFo CSIR – SRFo DST – JRFo DST - SRF

NOTE:

*. Candidates who have qualified in above said examinations leading to award of fellowships will begiven special weightage in the entrance examination as detailed in method of selection part ofguidelines.

Candidates working under Central Govt./Semi Govt./Autonomous organization should submittheir applications through proper channel i.e. employer. They will be required to submit a ‘NoObjection Certificate” from their employer before they are allowed to join the Ph.D. Course.

* The candidates who are likely to complete requisite qualification and degree by 30th

July, 2017 may also apply. However, the candidates who are completing theirrequisite qualification after 30th July, 2017 are not eligible to take up this examination

* Applicants from AIIMS Faculty/Scientific Staff for Ph. D. registration will be consideredas in-service candidates as per guidelines laid down by AIIMS in this regard.

* A candidate is allowed to submit application for one specialty/department only.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BATC

H 20

17PR

OSPE

CTUS

30

4. DURATION OF THE COURSE

(I) The duration of the course shall be the time period from registration to submission of thesis. Theminimum period of registration in respect of all the candidates who are registered for Ph.D. shallbe three years. The maximum period of registration shall not exceed five years. Extension beyondthe period of 5 years can be given for a maximum period of 6 months on the recommendation ofDean Committee and final approval by Dean/Director.

(II) Further extension beyond 5 years & 6 months can only be given by the Academic Committee for amaximum period of 6 months in highly exceptional circumstances (like medical exigencies, naturalcalamities etc.) and such extension may not be given retrospectively.

(III) The Chief guide of Ph.D Student shall give clear reason for the delay to the Academic Committee andmust present the case before Academic Committee.

(IV) In case of extension beyond 6 years without justifiable reasons and circumstances as mentionedabove, the PhD registration of the candidate shall be cancelled.

(V) Failure to submit thesis within stipulated time period of maximum 5yrs. with extension afterapproval upto 5½ years (6 years in exceptional circumstances by prior approval of AcademicCommittee) shall lead to cancellation of PhD registration of the candidate.

5. Centre for Examination : Examination will be conducted in Delhi/NCR only in through online (CBT)modes.

6. METHOD OF SELECTIONSelection for Ph.D. registration will be through a three-stage performance evaluation as under:

(I) Medical / Dental/Nursing candidates

Stage I : 30 Marks (30 MCQs of 1 Mark each) Aptitude related MCQs covering English(written and verbal skills), Biostatistics, Research Methodology, Cell Biology,Lab Technology etc.

Stage II : 40 Marks (40 MCQs of 1 Mark each) Subject related theory based comprisingMultiple Choice Questions (MCQs) of MD/MS/MDS/M.Sc. Entrance level.

Total Marks : 70 (30+40) - Stage I & IITotal Duration : 90 Minutes - Stage I & II

Stage III : Out of the candidates who secured 50 percent or above in the written test(Stage-I & II plus the special weightage), candidates 3 times the number of seatsadvertised will be called for departmental clinical/practical/lab based assessment(carrying 20 marks).

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BATC

H 20

17PR

OSPE

CTUS

31

Candidates holding Medical Degree (MBBS/DNB/MD/MS/DM/M.Ch.) or M.Sc. (Nursing) will begiven additional weightage of (10 marks). However, the marks of special weightage will only beadded to those candidates who will secure more than 50% or above marks in written test (StageI & II separately) to determine the merit.

(ii) Non-Medical candidates

Stage I : 30 Marks (30 MCQs of 1 Mark each) Aptitude related MCQs covering English(written and verbal skills), Biostatistics, Research Methodology, Cell Biology,Lab Technology etc.

Stage II : 40 Marks (40 MCQs of 1 Mark each) Subject relatedTotal Marks : 70 (30+40) - Stage I & IITotal Duration : 90 Minutes - Stage I & II

Stage III : Out of the candidates who secured 50 percent or above in the written test (Stage-I& II plus the special weightage), candidates 3 times the number of seats advertisedwill be called for departmental clinical/practical/lab based assessment (carrying 20marks).

Candidates who have qualified in any one of the following entrance tests in thelast 2 years will be given a weightage of (10 marks). Joint CSIR-UGC NET for JRF, ICMR-JRF,ICMR-SRF, DBT-JRF, DBT-SRF, NBHM screening test, Graduate aptitude test (GATE),

INSPIRE fellowship, UGC-JRF, UGC-SRF, CSIR-JRF, CSIR-SRF, DST-JRF, DST-SRF. However,the marks of special weightage will only be added to those candidates who will secure morethan 50% or above marks in written test (Stage I & II separately) to determine the merit.

(iii) Evaluation Procedure of Stage I & IIEach correct (MCQ) answer will be awarded 1 mark and each wrong (MCQ) answerwill be awarded one-third (-1/3) negative mark. More than one answer will betreated as wrong answer and awarded negative mark. Zero mark will be given forquestions not answered or marked for review.• Each correct response will get a score of 1 mark.• Each incorrect response will get a score of - 1⁄3 (minus-one-third).• No credit will be given for the questions not answered or marked for review.

CORRECT WRONG FORREVIEW

NOTANSWERED

+1 - ⅓ 0 0If any discrepancy in any question is found in the Entrance Examination, the candidate is advised towrite to Associate Dean (Exam), AIIMS, New Delhi – 110 608 within 24 hours on the following email: E-mail subdeanexamsaiims@hotmail.com. This mail will only be used for discrepancy related toquestion. However, for other query please mail on exams.ac@gmail.com

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

32

Note: I) The combined result of stage-I & stage-II will be available on website of theExamination Section, AIIMS and on website. No individual intimation will becommunicated to the candidate.

II) Candidates who fail to attend any of the stages of examinations as mentionedabove will not be eligible for admission.

III) Admission to Ph.D. Course will be subject to the availability of researchfunds/fellowship/ grant from recognized funding agencies.After declaration of results the selection letters issued by the Academic Sectiononly those candidates who has submitted Undertaking/Certificate proof of theirfunding sources through concerned Head of the Departments.

(iv) Method of Resolving TiesThe tie cases will be resolved according to age (Date of birth), the older candidate shall getpreference over the younger one.

Selected candidates are required to join on 01.10.2017 or before 14.10.2017. In case thecandidate fails to join by this date it will be assumed that he/she does not intend to join thecourse and the seat will be offered to the next candidate on the waiting list. No furthercorrespondence will be entertained in this regard. Last date of admission shall be 14.10.2017only. No further admission shall be allowed even from waiting list after 14.10.2017.

The Ph.D. Seats shall lapse if the selected candidates does not join by 14th October, 2017 forJuly session and no candidate shall be allowed to join after 14th October, 2017 for July sessionunder whatsoever circumstances.

7 RULES FOR ADMISSION FOR IN-SERVICE CANDIDATES – (NON-MEDICAL) APPLICABLE FOR AIIMSEMPLOYEES ONLY

The individual should be a regular employee of the institute and should have rendered aminimum of five years of continuous service at the institute. He/She should fulfil all the eligibility criteria for the Ph.D. course, and will appear in the entranceexamination and must score minimum of 50% marks. The individual should have 5 years of active service remaining in the institute. The candidate should have a proven track record of active involvement in research / academicactivities of the department. He/she should possess good written and verbal communication skills inEnglish language to be certified by HOD/Chief of Centre. The candidate should have at least 3 original research publications (not case reports) during thelast three years immediately preceding the date of his/her application either as a first author or as acommunicating author in a peer reviewed journal. The candidate will be considered as in-service candidate provided that the Head of theDepartment should certify that the work of the department will not suffer and no additional staffwill be asked for.

IMPORTANT

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

33

The candidate seeking admission under this category will have to identify a faculty member in theInstitute who is willing to be the chief-guide of the candidate. The candidate should submit a letterof acceptance/undertaking from the concerned faculty member in this regard.

1. LEAVES AND OTHER RULES

The Ph.D. students are entitled for 30 days leave every year, if leave availed exceed the limit within ayear, then the extended period is treated as Extra Ordinary Leave and his/her minimum registrationwill be extended for the same duration.

However, extraordinary leave cannot be more than 3 months in the entire registration period of 5years. Any such extension beyond 3 months shall lead to the registration being cancelled. Thefemale candidates shall be entitled for maternity leave etc as per existing rules.

In case the Chief Guide recommends a candidate for specific training or project related work outsideAIIMS (within India or abroad), the leaves shall be treated as on duty/Study leave. This study leaveshall not be more than 6 months in the entire registration period. The proof of acceptance of thecandidate for such training/work outside should be submitted and on return, the report of suchtraining/work done shall be required to be submitted to the Dean, by the candidate through thechief guide.

1. INSTRUCTIONS FOR FILLING THE ONLINE APPLICATION FORMCandidate should fill in the Online Application Form taking utmost care and follow the instructions and helpmanual as given in the APPENDIX - II of the Prospectus, step by step. Candidate should fill in the OnlineApplication form correctly. Incorrect filled form may leads to rejection.

2. ONLINE REGISTRATION & SUBMISSION OF APPLICATION FORMA candidate seeking admission to the Entrance Examination is required to submit his/her application in theprescribed format available online with the Prospectus on www.aiimsexams.org. The cost of Application Formincludes the fee for entrance examination which is non-refundable and no correspondence in this regard will beentertained. The candidate is required to go through the Prospectus carefully and acquaint himself/herself withall requirements with regard to filling of the online application form.Online Registration: After selecting the online registration, fill the mandatory details asked for and deposit theprescribed fee through debit/credit card/Net Banking. After submitting fees filled required information step bystep. Follow the Instructions scrupulously.It will be the responsibility of the candidates to ensure that correct details are filled in the Registration Form. TheInstitute will not be responsible for any incorrect information/cancellation of candidature/loss or lack ofcommunication etc. due to wrong filled online Application form.No candidate should register more than one application.All applicants are required to ensure that Photo/Signature/Left Thumb Impression is uploaded accordingto the instructions provided in the Prospectus. Failure to do so may result in rejection of applications.Duplicate applications from any applicant will result in cancellation of all such applications. Nointimation regarding such summary rejections will be provided.

IMPORTANT INSTRUCTION APPLICABLE TO Ph.D PROGRAMME EXAMINATIONIV

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

34

3. STATUS OF ONLINE REGISTRATIONAcknowledgement of successful Online Registration will be forwarded to applicant’s Registered Email ID. TheRegistration Form will remain Under Review regarding uploaded images and eligibility. However, candidatescan check their status of uploaded images within two working days from the date of online Registration is doneand subsequent further status updates. The rejected images can be updated till the registration is open.The candidates are advised to check final status of their Registration Form regarding images and eligibility andAdmit Card which will be available on AIIMS website www.aiimsexams.org as per the schedule mentioned inthe “IMPORTANT DATES AT A GLANCE”.Admit Card for Accepted Registration Form will only be uploaded on the website. If the status ofRegistration Form or Admit Card is not available on website, he/she should immediately write an email tothe Assistant Controller of Examinations, AIIMS, New Delhi-110608 on exams.ac@gmail.com along withfull particulars of the Registration Form.

4. DOCUMENTS TO BE ATTACHED WITH REGISTRATION FORMI) No document is required, except the following applicability:

(i) Sponsored Candidates and Foreign nationals.

1) Sponsorship Certificate (in the case of sponsored candidate) in the format prescribed inthe Prospectus, duly completed and signed by the competent authority.

2) NOC from Ministry of Health & Family Welfare in case of Foreign National.

Note: Sponsored/Foreign national category candidates should send the above documents in aseparate envelope to the Asstt. Controller (Examinations), Examination Section, AIIMS,Ansari Nagar, New Delhi - 110 608 indicating their Registration No. on the top of the envelopeand on the documents followed by the name of course/discipline applied for.

(ii) The candidates qualified in Stage – I & Stage- II result and called for Departmental Assessmentmust submit attested copies of the required documents in support of their claims of educationalqualifications, marks, date of birth, category, experience etc. on the specific day mentioned in theStage I result of the written test By Hand to the Examination Section, 1st Floor, Convergence Block,AIIMS, New Delhi.

If a candidate fails to submit attested copies of the requisite documents as above, his/hercandidature will be cancelled and he/she will not be allowed to participate in subsequent stagesof selection/admission process.

5. SUBMISSION OF APPLICATION BY CANDIDATES WHO ARE EMPLOYED

The candidates in employment applies for Ph.D. Programme are required to submit their applications throughproper channel. They should also sign the undertaking in the down loaded copy of Registration Form that theyhave informed their employer about the submission of the application to AIIMS. If any communication is receivedfrom their department/office withholding permission to the candidate's appearing at the entranceexamination/admission to the course, the candidature/admission of the candidate will be cancelled, and nofurther correspondence in this regard will be entertained. (Sponsored candidates for Ph.D. Programme arerequired to route their Registration Form through proper channel).6. REQUIREMENTS FOR ADMISSION OF "SPONSORED" CANDIDATESa) Candidates who are permanent employees of any Central/State Government/Armed Forces or the

Public Sector Undertaking/Autonomous Body can be sponsored by the respectiveGovernment/Defence Authorities or the Competent Authorities of PSU/Autonomous Body.

b) All eligible "sponsored" candidates will be called by the Institute for an entrance test.c) Seats as shown in the prospectus are available for "sponsored" candidates. Sponsored candidates will be

designated as "trainees".d) The subject for which the candidate is being sponsored should be clearly specified in the sponsorship form

by the sponsoring authority. The candidate can be sponsored for only one subject. The applications ofthose candidates who are sponsored for more than one subject will not be considered.

e) No "Sponsored" candidate will be paid any emoluments by the Institute during the training period. Suchpayments will be the responsibility of the sponsoring authority (i.e. Central/State Government or DefenseAuthorities).

f) Sponsored candidates must submit/send sponsorship certificate in original from their employers in thefollowing format along with the application form to the Asstt. Controller (Examinations), AIIMS, AnsariNagar, New Delhi - 110 608. Those who fail to do so should submit it before the date of issue of AdmitCards as mentioned under "AT A GLANCE" in the Prospectus failing which their candidature will becancelled.

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

35

7. REQUIREMENTS FOR ADMISSION OF FOREIGN NATIONALS/OVERSEAS CITIZEN OF INDIA (OCI)a) Foreign nationals are required to fill in the prescribed online application form indicating the choice of subject

(only one subject) for admission to Postgraduate courses leading to award of Ph.D. Programme degree.b) The foreign nationals are required to send their Registration Form of Online application through Diplomatic

Channel. They are also required to appear in the Competitive Entrance Examination along with othercandidates. An ‘Advance Copy’ to be submitted at AIIMS, New Delhi before the last date of onlineregistration. However the application of all such candidates will be processed only after receipt of the samethrough Diplomatic Channel.

c) The foreign nationals will be considered against the seats advertised under the "Sponsored" category forPh.D. Programme. They should be registered with MCI before they will be allowed to join the said course.If they are selected for the same.

d) Seats are not reserved in any discipline for foreign nationals (except the bilateral agreement between theGovernment of India and any other nation).

e) Nominations/No objection for the candidate should reach the Examination Section before the date of issueof the Admit Card as specified under "AT A GLANCE". In case of non-receipt of thenominations/clearance/no objection from the concerned Ministry by due date, their candidature will not beconsidered.

f) No emoluments will be paid by AIIMS to the Foreign National candidates.g) OVERSEAS CITIZEN OF INDIA (OCI) : OCI registered under Section 7A of Citizenship Act 1955 are also

eligible to appear in PG courses and all terms and conditions applicable for Indian Nationals will beapplicable to the candidates. The candidate will submit proof of Registration as OCI under Section 7A ofCitizenship Act 1955 to be eligible to appear for this test.

8. SUBMISSION OF CASTE CERTIFICATE BY SC/ST/OBC CANDIDATES

After declaration of result of the Entrance Examination, candidates belong to Scheduled Caste/Scheduled Tribeand Other Backward Classes should submit, along with other requisite documents, an attested copy of acertificate from any one of the following authorities stating that the candidate belongs to Scheduled Caste,Scheduled Tribe or Other Backward Classes in the prescribed form.A. District Magistrate, Additional District Magistrate, Collector, Deputy Commissioner, Additional Deputy

Commissioner, Deputy Collector, 1st Class Stipendiary Magistrate, City Magistrate, Sub-DivisionalMagistrate, Taluka Magistrate, Executive Magistrate, Extra Assistant Commissioner.

B. Chief Presidency Magistrate/Additional Chief Presidency Magistrate/Presidency Magistrate.C. Revenue Officer not below the rank of Tehsildar.D. Sub-Divisional Officer of the area where the candidate and his or her family normally resides.E. Administrator/Secretary to Administrator/Development Officer (Lakshadweep Island) or as authorised in the

Constitution.The candidate will be required to submit an undertaking to the effect of their caste. The detection of anydiscrepancy in the caste certificate shall entail cancellation of registration. This is as per the provisions made byMinistry of Personnel, Public Grievances and Pensions vide their order No. 36033/4/97-Estt. (RES) dated25.7.2003 and No. 36011/3/2005-Estt. (RES) dated 9.9.2005 respectively.Candidates must note that a certificate from any other person/authority will not be accepted and nofurther correspondence in this regard shall be entertained. The name, designation and the seal of theofficer should be legible in the certificate.

9. PROCEDURE FOR REDRESAL OF DISCREPANCY NOTICED:(i) If any discrepancy in any question is found in the Entrance Examination, the candidate is advised to

write to Associate-Dean (Exams), AIIMS, New Delhi–110608 within 24 hours onsubdeanexamsaiims@hotmail.com.

(ii) Discrepancy, if any, in the Prospectus, Admit Card etc. should be immediately brought to the notice ofthe Assistant Controller (Examinations) AIIMS, New Delhi through email exams.ac@gmail.comComplaints received after the examination will not be entertained.

10. It will be the responsibility of the candidate to ensure that correct address, Mobile No. & email ID in theApplication Form is filled. The Institute shall not be responsible for any miscommunication due to incorrectaddress, Mobile No. and email ID given by the applicant on the Application Form or non-receipt for anycommunication.

11. Downloadable Admit cards of all the eligible candidates will be hosted on websitewww.aiimsexams.org as per the schedule mentioned under ‘AT A GLANCE’. All the candidates areadvised to download their Admit Cards from the website. It may please be noted that the AdmitCards will not be sent by Post.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

362

12. Any Change in the address mobile No. and email ID should be immediately intimated to this office byregistered mail Candidate should also ensure that any communication sent at the previous address isredirected to him/her at the new address.

13. If a candidate is at any stage found to have provided false information/certificate or is found to havewithheld or concealed some information in his/her application form, he/she will be debarred from admission,his/her residency will be terminated with immediate effect.

14. If ineligibility is detected at any stage, candidature/admission of the candidate will be cancelled without anynotice.

15. Candidate must not obtain or give or attempt to obtain or give irregular assistance of any kind during theexamination; this will entail expulsion and cancellation of candidature for the examination. The admission ofthe candidate will be cancelled and appropriate criminal/civil proceedings will be initiated against thecandidates, if at any stage of the examination the candidate is found to have secured admission by usingany unfair means.

16. The Institute will not intimate the result of Entrance Test individual. No correspondence in this regard willbe entertained. However, the marks of individual candidate will be made available on AIIMS websitewww.aiimsexams.org on completion of the admission process.

17. There is no provision for re-checking/re-evaluation of the answer sheets and no query in this regard will beentertained.

18. The decision of the Director of the Institute shall be final in the matter of selection of candidates foradmission to Ph.D. Programme and no appeal will be entertained in this regard.

19. Selected candidates must join the course on the date stipulated in the letter of selection, failing which theselection/admission shall stand cancelled/withdrawn.

20. The selected candidates will have to submit the original Permanent Registration Certificate at the time ofjoining.

21. The selection of students in Ph.D. Programme will be subject to medical fitness. No selected candidatewill be permitted to pay fee/join the course unless declared medically fit by the Medical Board appointed bythe Institute. The decision of the Medical Board shall be final.

22. Each candidate selected for admission shall have to pay the fee/dues within the prescribed period failingwhich his/her admission shall be cancelled.

23. Private practice in any form during the course is prohibited. The period of training is strictly full time andcontinuous.

24. The rules are subject to change in accordance with the decision of the Institute to be taken from time totime.

25. Any dispute in regard to any matter referred to herein shall be subject to the jurisdiction of DelhiCourts alone.

1. FEES

Each candidate selected for admission will have to pay the following Course duration Fees and dues:

DURATION1. Registration Fee : Rs. 25/-2. Tuition Fee

Ph.D. : Rs. 720/- 3 Years3. Laboratory Fee

Ph.D. : Rs. 120/- 3 Years4. Pot Money

Ph.D. : Rs. 720/- 3 Years5. Hostel Rent

For all Ph.D. Students : Rs. 1080/- 3 Years6. Electricity

Ph.D. : Rs. 240/- 3 Years7. Gymkhana Fee

Ph.D. : Rs. 120/- 3 Years8. Caution Money : Rs. 100/-

(to be deposited by every student for the recoveryof breakages or loss of Institute’s equipment).

9. Hostel Security : Rs. 1000/- (Refundable)

(All Fees and dues payable at the time of admission)

GENERAL INFORMATIONV

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

37

Note: 1. The Hostel Security deposit (refundable) i.e. Rs. 1000/-Note: 2. Fees and other charges including hostel rent once paid shall not be refunded in any case

and no correspondence will be entertained in this connection. However, the caution moneywill be refunded to those candidates who do not join the course. The caution money must beclaimed within one year after completion of the course failing which it will be forfeited.

2. HOSTEL ACCOMMODATIONThe unmarried Ph.D. students will be provided partially furnished accommodation subject toavailability. Those married and living with family will be provided, subject to availability, partiallyfurnished married hostel accommodation on recovery of rent as per rules of A.I.I.M.S. However, thesponsored Ph.D. students will be charged a sum of Rs. 450/- per month for single room hostelaccommodation and a sum of Rs. 650/- per month for married hostel accommodation.3. INSTITUTE LIBRARYThe Institute library is well stocked with all important medical books and journals. Other facilities includephotocopying, Medline, video monitor facilities and modern learning resources materials (LRM). Booksand periodicals are loaned to bonafide members for a specified period of time.The National Medical Library is also situated in the vicinity of the Institute campus.

4. CODE OF CONDUCT FOR Ph.D. STUDENTS AT AIIMS, NEW DELHI

(i) Maintenance of Discipline among students of the AIIMS :

1. All powers relating to discipline and disciplinary action are vested with the Director, AIIMS.2. The Director, AIIMS may delegate all such powers, as he/she deems proper to the Dean and

to such other persons as he/she may specify on his behalf.3. Without prejudice to the generality of power to enforce discipline under the Rules. The

following shall amount to acts of gross indiscipline :a) Physical assault or threat to use physical force against any member of the teaching or

nonteaching staff of any Department/Centre of AIIMS or any other persons within thepremises/ Campus of AIIMS.

b) Carrying or use or threat of use of any weapon.c) Violation of the status, dignity and honour of students belonging to the Scheduled Castes,

Scheduled Tribes and Other Backward Castes.d) Any practice, whether verbal or otherwise, derogatory to women.e) Any attempt at bribing or corruption in any manner.f ) Willful destruction of institutional property.g) Creating ill-will or intolerance on religious or communal grounds.h) Causing disruption in any manner of the functioning of the AIIMS, New Delhi.i) Regarding ragging the directive of Supreme Court will be followed strictly. It is as

under :"As per direction of the Hon'ble Supreme Court of India, the Government has bannedragging completely in any form inside and outside of the campus and the Instituteauthorities are determined not to allow any form of the ragging. Whoever directly orindirectly commits, participates in abets or instigates ragging within or outside anyeducational Institution, shall be suspended, expelled or rusticated from the Institutionand shall also be liable to fine which may extend to Rs. 10,000/-. The punishment mayalso include cancellation of admission suspension from attending the classes,withholding/withdrawing fellowship/ scholarship and other financial benefits,withholding or cancelling the result. The decision shall be taken by the Head of theInstitution."

4. Without prejudice to the generality of his/her powers relating to the maintenance of disciplineand taking such action in the interest of maintaining discipline as may seem to him/herappropriate. The Director, may in exercise of his/her powers aforesaid order or direct that anystudent or students.a) Be expelled;b) Be, for a stated period : be not for a stated period, admitted to a course or courses of

study in AIIMS.c) Be fined with a sum of rupees that may be specified;d) Be debarred from taking any examination(s) for one or more semesters.e) Withhold the result of the student(s) concerned in the Examination(s) in which he/she or

they have appeared be cancelled.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

38

f ) Be prohibited for appearing or completing any examination for any unfair means likecopying taking notes, mobiles or any other electronic gadgets inside the examination halls.

5. At the time of admission, every student shall be required to sign a declaration that onadmission he/she submits himself/herself to the disciplinary jurisdiction of the Director andseveral authorities of the AIIMS who may be vested with the authority to exercise disciplineunder the Acts, the Statutes, the Rules and the rules that have been framed there under bycompetent authorities of AIIMS.

(ii) Prohibition of and Punishment for Ragging :1. Ragging in any form is strictly prohibited, within the premises of College/Department of

Institution and any part of AIIMS and also outside the AIIMS Campus.2. Any individual or collective act or practice or ragging constitute gross indiscipline shall

be dealt with under this Rules.3. Ragging for the purposes of this rules, ordinarily means any act, conduct or practice by

which dominant power or status of senior students is brought to bear on studentsfreshly enrolled or students who are, in any way, considered junior or inferior by otherstudents and includes individual or collective acts or practice which :a) Involve physical assault or threat or use of physical force;b) Violate the status, dignity and honour of women students;c) Violate the status; dignity and honour of students belonging to the Scheduled

Castes, Scheduled Tribes and Other Backward Castes.d) Expose students to ridicule and contempt and affect their self-esteem;e) Entail verbal abuse and aggression, indecent gesture and obscene behavior.

4. The Director, Dean, Hostel Superintendent and Faculty of AIIMS shall take immediateaction on any information of the occurrence of ragging.

5. Notwithstanding anything in Clause (4) above, the Dean or any other Facultymember/or authority may also suo moto enquire into any incident of ragging and makea report to the Director of the identity of those who have engaged and the nature of theincident.

6. The Dean may also submit an initial report establishing the identity of the perpetratorsof ragging and the nature of the ragging incident.

7. On the receipt of a report under clause (5) or (6) or a determination by the relevantauthority disclosing the occurrence or ragging incidents described in the Clause 3(a),(b) and (c) the Director shall direct or order rustication of a student or students for aspecific number of semester.

7. The Director may in other cases of ragging order or direct that any student or studentsbe expelled or be not, for a stated period, admitted to a course of study as AIIMS,departmental examination for one or more semesters or that the result of the student orstudents concerned in the examination(s) in which they appeared be cancelled.

8.9. In case where students who have obtained degree(s) of AIIMS are found guilty under

this Rules, appropriate action will be taken for withdrawal of degrees conferred by theAIIMS.

10. For the purpose of this Rules, abetment to ragging will also amount to ragging.

(iii) Anti Sexual Harassment Monitoring Committee :A statutory committee, comprising of members from the teaching and non-teaching staff aswell as students looks into matters related to sexual harassment of students and staff in thecollege. Any person aggrieved in this matter may fearlessly approach the committee for afair and concerned hearing and redressal.

(iv) Unauthorised absence of students :Unauthorised absence of students will be informed to the Students and also Parents orLocal Guardians. At least 3 reminders will be issued with a gap of 10 days by the AcademicSection to these students. Thereafter the action of cancellation of the registration of theconcerned will be decided by the Dean/ Director, AIIMS.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

39

Code States / U. T. Code States / U. T.01 Andhra Pradesh 19 Mizoram02 Arunachal Pradesh 20 Nagaland03 Assam 21 Orissa04 Bihar 22 Punjab05 Chhattisgarh 23 Rajasthan06 Delhi 24 Sikkim07 Gujarat 25 Tamil Nadu08 Goa 26 Telangana09 Haryana 27 Tripura10 Himachal Pradesh 28 Uttar Pradesh11 Jammu & Kashmir 29 Uttarakhand12 Jharkhand 30 West Bengal13 Karnataka 31 Andaman & Nicobar14 Kerala 32 Chandigarh15 Madhya Pradesh 33 Dadra & Nagar Haveli16 Maharashtra 34 Daman and Diu17 Manipur 35 Lakshadweep18 Meghalaya 36 Puducherry

APPENDIX - I - STATE CODEVI

AIIM

SPh

.D. P

ROGR

AMM

E JA

NUAR

Y BA

TCH

2017

PRO

SPEC

TUS

40

User Manual[Important Instructions for Applicants filling AIIMS - Ph.D. Programme July - 2017

Session Online Registration Form]

Open the website of All India Institute of Medical Sciences. The URL of the website ishttp://www.aiimsexams.org.

The home page as shown below appears on the screen.

APPENDIX - IIVII

AIAI

IMS

Ph.D

. PRO

GRAM

ME

JULY

BAT

CH 2

017

PROS

PECT

US

41

Registration After opening the website, the next step is Registration. By clicking on Academic Courses Tab an Applicant can navigate to the desired course i.e. Ph.D. to

registered him/her self.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

42

For New Registration, click on Click Here button on New Registration Page.

For already registered candidate, enter Candidate Id, Password (already sent on registered email id) and Captchaand then click on Login button.

Applicant must ensure that their mobile number is not registered with DND (Do Not Disturb) service. Applicantmust check his/her Email Inbox, Junk mail and Spam after registration to get Login Credential for completeregistration process.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

43

Step 1: Registration

On clicking the “Proceed” button Next page shown will be the New Candidate Registration Form.

(All #marked fields are optional).

Select the desired course.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

44

Read the Declaration of Eligibility carefully and give consent on it before submitting the form.

After filling the required information then click on “Register” button. After Click on register button amessage will appear on screen containing ‘Candidate ID’ and ’Password’. An Email and SMS will also besent to registered E-mail Id and mobile number having Login Credentials i.e. Candidate ID and password.

Please note this candidate id for future references.

i)Change Password

Login with the provided login Credentials i.e. Candidate Id and Password and correct Captcha. On first timelogin, candidate has to change password Change Password through Change Password page. Re-login withthe new changed password to complete due steps of Registration Process.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

45

Information Page

After re-login the next page appears will page will show the all Seven (7) steps of Registration Process. First stepis new candidate Registration for Ph.D. July 2017 Session.

The color of the Number of the Step in Navigation Bar will change from Red to Yellow as the steps getcompleted and candidate can jump/go to any steps among the completed steps at any time.

Color will change from Red to Yellow as a step of registration gets completed

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

46

iii) Edit Information Page

Candidate should re-check the filled in information, in case there is some error in the information filled in the formCandidate can edit some information by clicking on Registration Yellow Wizard. It will redirect candidate toRegistration page where some information can be edited.

After click on Update button, Candidate will be navigated to Candidate Dashboard Page.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

47

Step 2: Qualification Details

After first step of registration process is completed, the next step is to fill Qualification Details. Candidateshould fill all the information asked for regarding Qualifying Examination, Internship and Medical Registration.After fill all required filled then click on Save and Proceed button.

Click on Save and Proceed Button to fill Experience Details.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

484

Step 3: Experience Details

After fill the Qualification Details, next step is Experience Details. Candidate has to fill requirement detailsrelated to Experience as desired according to the course applied for.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

49

Step 4: City Choice

The Fourth step is City Choice. After filling Experience details candidate will be directed to City Choice Page.

Click on Proceed button for payment of Registration Fee.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

50

Step 5: Make Payment

After Centre Choice, candidates will be navigated to Payment page to make payment of registration Fee.Payment of registration fee can only be done through Online Mode i.e. Debit/Credit card and InternetBanking.

Login with your credentials of net banking for fee payment, and click on submit button to proceed for payment.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

51

Candidate should enter the information asked for to pay through on line mode and click on PAY button.

Candidate must remember to take printout of Payment Receipt as a proof of payment by clicking on Print button.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

52

Step 6: Upload Images

After Successful Payment Confirmation, Candidate needs to upload their latest passport size Photograph,Signature and Thumb Impression. The supported digital image format includes gif, png, jpg/jpeg.

Upload Images

First read the instructions given regarding Photo, Signature and Thumb Impression upload. To upload imageclick Choose File button and browse to path where the image is stored. You can see the preview of theuploaded images. Please refer to Sample Images provided on the page, if you are satisfied with the preview ofimages, click on Accept button else try again to upload the images. After uploading all three required images,give consent on the declaration and click on Save & Proceed button. Images once uploaded cannot bechanged later so candidates are requested to pay due attention while uploading the images.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

53

Step 7: Print Registration Form

The seventh and the Last Step is Print Registration Form. Candidate must take print of Registration Slip onceall steps of registration are completed. Click on Submit button and take printout of Registration Form.

Registration Form contains all the details provided by candidate during on line registration i.e. PersonalDetails, Qualification Details, Experience Details, Payment details and Uploaded Images etc.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

542

Check all the details in Registration Form carefully, if some entered information is to be corrected/ editedthen click on edit button, do the necessary corrections and then click on Final Submit button.

Take the print of the Registration Slip after final submission of form. Candidate can take the print out of theRegistration Form by clicking on Print button

AIIM

SPh

.D. P

ROGR

AMM

E JA

ULY

BATC

H 20

17PR

OSPE

CTUS

55

After clicking Final Submit button, color of navigation bar of all the steps of registration process will change toYellow from Red.

After completing all 7 steps of registration candidate will be registered successfully and can navigate to anycompleted step through Navigation Buttons available on top of the page. Candidate should Logout afterregistration is done successfully.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

56

Candidates are required to upload their Photograph, Signature and Left ThumbImpression during Online Registration.

PHOTOGRAPH:

1. One (1) recent color passport size photograph with white background is required.The dimensions of the photograph should be 3.5*4.5 cms (width*height).

2. Black & White / Polaroid photographs are NOT acceptable. Photograph should not betaken by mobile phone camera.

3. Photograph should be taken professionally, so that it may not blur while enlarging it.

4. Photograph MUST be taken recently and should not be taken more than six monthsprior from the start of Online Registration.

5. Draw a box having size 3.5 x 4.5 cms (width*height) on a plain white sheet and pastethe photograph inside the box.

6. Select the area having photograph only, not the whole sheet and scan the photographon 200 dpi.

7. Save the scanned image as “Photograph.jpg" (supported formats include jpg/ jpeg, gif,png). Keep the size of image between 10 KB to 100 KB.

UPLOADING PHOTOGRAPH:

Candidates must upload Photograph to correct specified field. Do not make any mistake inuploading Photograph

1. To upload "Photograph.jpg"

a. Click "Choose File" button right to the photograph field.b. Select the scanned "Photograph.jpg" file from saved location and click "Open"

button.

INSTRUCTION FOR UPLOADING IMAGESVIII

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

57

While uploading images during Online Registration, please refer followingNot Acceptable/ Acceptable sample images.

AIIM

SPh

.D. P

ROGR

AMM

E JA

NUAR

YBA

TCH

2017

PRO

SPEC

TUS

58

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

59

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

60

SIGNATURE:

1. Draw a box of size 6 x 3 cms (width * height), on a plain white sheet and put thesignature inside the box.

2. Signature should be done with thick point Black/Blue pen only. Signatures havingonly Initials or done in CAPITAL letters are not acceptable.

3. Scan the area having signature only not the whole sheet. Scan the signature on 200dpi. It should not be blurred while enlarging it.

4. Save the scanned image as "Signature.jpg". Supported formats of the imageinclude jpg/jpeg, gif, png. Keep the size of the image between 10 KB to 50 KB.

UPLOADING SIGNATURE:Candidates must upload Signature to correct specified field. Do not make anymistake in uploading Signature.

1. To upload "Candidate Signature.jpg"

a. Click “Choose file” button right to the signature field.b. Select the scanned "Signature.jpg" file from saved location and click "Open"

button.

While uploading Signature during Online Registration, please refer followingNot Acceptable/ Acceptable sample Signature images.

Signature Properly uploaded signature that is inblack with white background. Thesignature is clear and of proper size.

Signature

NOT ACCEPTABLE: Signature uploadedis very small

Signature NOT ACCEPTABLE: Signature is incoloured ink

Signature NOT ACCEPTABLE: Signature uploadedis too light and unclear

Signature NOT ACCEPTABLE: Signature uploadedalongwith background

Signature NOT ACCEPTABLE: Signature uploadedis partly obscured by marks / sprinkledink

NOT ACCEPTABLE: Signature uploadedis blurred

NOT ACCEPTABLE: Signature is cropped/ not scanned properlySignature

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

61

LEFT THUMB IMPRESSION:

1. Draw a box of size 4 x 3 cms (width * height) on a plain white sheet.

2. Take a good quality Blue/Black ink stamp pad.

3. Put your left thumb gently on the stamp pad and role lightly in horizontal manner.

4. The lines of the finger should be clearly visible in the print.

5. Scan the area of white sheet having thumb impression only, not the whole sheet.

6. Scan the left thumb impression on 200 dpi. It should not be blurred while enlarging it.

7. Save the image as "Left Thumb Impression.jpg". Supported formats of the image

include jpg/jpeg, gif, png.

8. Keep the size of image between 10 KB to 50 KB.

UPLOADING LEFT THUMB IMPRESSION:

Candidates must upload Left Thumb Impression to correct specified field. Do not make anymistake in uploading Left Thumb Impression.

1. To upload "Candidate Left Thumb Impression.jpg"

a. Click “Choose file” button right to the Left Thumb Impression field.b. Select the scanned "Left Thumb Impression.jpg" file from saved location and

click "Open" button.

While uploading Left Thumb Impression during Online Registration, please referfollowing Not Acceptable/ Acceptable sample Left Thumb Impression images.

Properly uploaded Left Thumb Impressionin .jpg. The Left Thumb Impression is clearand of proper size.

NOT ACCEPTABLE: Left Thumb ImpressionLeft Thumb Impression uploaded isblurred.

NOT ACCEPTABLE: Left Thumb Impressionuploaded is partly obscured by too muchink.

NOT ACCEPTABLE: Left Thumb Impressionuploaded is partly cropped / not scannedcompletely

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

62

1. I certify that Dr./Miss/Mrs./Mr.* ______________________________ is being sponsoredfor training leading to the award of Ph.D Programme in _______________________atAll India Institute of Medical Sciences for the session commencing in July 2017.

2. That Dr./Miss/Mrs./Mr.* ______________________________ is a permanent employeeof _______________________ (name of the State/Central Govt. Dept./Office/ArmedForces/ the Competent Authorities of PSU/Autonomous Body etc.)

3. That Post Graduate [Ph.D Programme] course for which the candidate is beingsponsored.

4. That he/she after getting the training at the AIIMS will be suitably employed by thesponsoring authority in the speciality in which training is to be provided in All IndiaInstitute of Medical Sciences.

5. That the candidate will be paid all emoluments by the sponsoring authority during theentire training period. Such payment will not be the responsibility of the All India Instituteof Medical Sciences.

6. That the candidate is being sponsored for the entire duration of the course as specified inthe prospectus for the above mentioned course.

Signature of _____________________________Sponsoring authority

Date : _____________ Name __________________________________(in BLOCK LETTERS)

Place : ___________ Designation ____________________________

Office Seal _____________________________

*Delete whichever is not required.

IMPORTANT:

(i) The above certificate, duly signed only by the Competent Authority i.e.Secretary/Director General of Health Services of the Central/State Governmentconcerned/ DGAFMS/ Director/ Executive Head, will be considered.

(ii) No addition or alteration in the above certificate is allowed.(iii) Subject/Discipline must be specified in the sponsorship certificate failing which the

candidature will not be considered under the sponsored category.

NOTE 1: While sponsoring the candidates, the Central/State Government/DefenceAuthorities /PSU/ Autonomous Bodies should furnish a certificate prescribed forthis purpose duly completed and signed by the competent authority.

NOTE 2: The 'Sponsorship Certificate' should indicate the discipline/speciality for which thecandidate is being sponsored, failing which the application will not be consideredunder the Sponsored Category.

FORMAT OF SPONSORSHIP CERTIFICATE BY CENTRAL/STATE GOVT./ARMED FORCES(SPONSORING AUTHORITIES)

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

63

PROFORMA FOR OTHER BACKWARD CLASS (OBC) CERTIFICATE(Certificate to be Produced by other Backward Classes applying for Admission to Central Educational

Institutions (CEIs), Under The Government of India)

This is to certify that Shri /Smt./Kum.__________________________________________________Son/Daughter ofShri/Smt.______________________________of Village/Town__________________District/Division_______ in the____________________________State belongs to the _______________________Community which is recognizedas a backward class under:

(i) Resolution No. 12011/68/93-BCC(C) dated 10/09/93 published in the Gazette of India Extraordinarypart I Section I No. 186 dated 13/09/93.

(ii) Resolution No. 12011/9/94-BCC dated 19/10/94-BCC dated 19/10/94 published in the Gazette ofIndia Extraordinary part I Section I No. 163 dated 20/10/94.

(iii) Resolution No. 12011/7/95-BCC dated 24/05/95 published in the Gazette of India Extraordinarypart I Section I dated 25/05/95.

(iv) Resolution No. 12011/96/94-BCC dated 09/03/96.(v) Resolution No. 12011/44/94-BCC dated 06/12/96 published in the Gazette of India Extraordinary

part I Section I No. 210 dated 11/12/96.(vi) Resolution No. 12011/13/97-BCC dated 03/12/97.(vii) Resolution No. 12011/99/94-BCC dated 11/12/97.(viii) Resolution No. 12011/68/98-BCC dated 27/10/99.(ix) Resolution No. 12011/88/99-BCC dated 06/12/99 published in the Gazette of India Extraordinary

Part I Section I No. 270 dated 06/12/99.(x) Resolution No. 12011/36/99-BCC dated 04/04/2000 published in the Gazette of India Extraordinary

Part I Section I No. 71 dated 04/04/2000.(xi) Resolution No. 12011/44/99-BCC dated 21/09/2000 published in the Gazette of India Extraordinary

Part I Section 1 No. 210 dated 21/09/2000.(xii) Resolution No. 12015/09/2000-BCC dated 06/09/2001.(xiii) Resolution No. 12011/01/2001-BCC dated 19/06/2003.(xiv) Resolution No. 12011/04/2002-BCC dated 13/01/2004.(xv) Resolution No. 12011/09/2004-BCC dated 16/01/2006 published in the Gazette of India Extraordinary Part

I Section I No. 210 dated 16/01/2006.

Shri/Smt./Kum. _________________________and/or his family ordinarily reside(s) inthe__________________________ District/Division of ___________________________ State.This is also to certify that he/she does not belong to the persons/sections (Creamy Layer) mentioned in Column 3of the Scheduled to the Government of India. Department of Personnel & Training O.M. No. 36012/22/93-Estt.(SCT ) dated 08/09/93 which is modified vide OM No. 36033/3/2004 Estt. (Res.) dated 09/03/2004 or the latestnotification of the Government of India.Dated :

District Magistrate/Competent Authority SealNOTE:

(a) The Term Ordinarily used here will have the same meaning as in Section 20 of the Representationof the People Act, 1950.

(b) The authorities competent to issue Caste Certificates are indicated below:(i) District Magistrate/Additional Magistrate/Collector/Deputy Commissioner/Additional Deputy

Commissioner/Deputy Collector/Ist Class Stipendiary Magistrate/Sub-Divisional Magistrate/Taluka Magistrate/Executive Magistrate/Extra Assistant Commissioner (not below the rank ofIst Class Stipendiary Magistrate.)

(ii) Chief Presidency Magistrate/Additional Chief Presidency Magistrate/Presidency Magistrate.(iii) Revenue Officer not below the rank of Tehsildar.(iv) Sub-Divisional Officer of the area where the candidate and/or his family resides.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

64

FORM OF SC/ST CERTIFICATE PRESCRIBED

Form of certificate as prescribed in M.H.A., O.M., No. 42/21/49-N.G.S. dated the 28.1.1952, as revised in Dept. of Per-&A.R. letter No. 36012/6/76-Est. (S.CT), dated the 29.10.1977, to be produced by candidate belonging to a ScheduledCaste or a Scheduled Tribe in support of his/her claim.

CASTE CERTIFICATEThis is to certify that Shri/Smt./Kum.*.............................................................. son/daughter*of................................ofvillage/town*........................................in district/Division*..............................of the State/Union Territory*................................................ belongs to the ...............................Caste/Tribe which is recognised as a ScheduledCaste/Scheduled Tribe* under : The Constitution (Scheduled Caste) Order, 1950 The Constitution (Scheduled Tribe) Order, 1950 The Constitution (Scheduled Caste) (Union Territories) Order, 1951 The Constitution (Scheduled Tribe) (Union Territories) Order, 1951% 1. (as amended by the Scheduled Caste and Scheduled Tribes Lists (Modification) Order, 1956, the Bombay Re-organization Act, 1960, the Punjab Re-organization Act, 1966, the State of Himachal Pradesh Act, 1970 the North EasternAreas (Re-organization) Act, 1971 and the Scheduled Castes and Scheduled Tribes Orders, (Amendment) Act, 1976). TheConstitution (Jammu and Kashmir) Scheduled Caste Order, 1956. The Constitution (Andaman and Nicobar Islands) Scheduled Tribes Order, 1959. The Constitution (Dadra and Nagar Haveli) Scheduled Caste Order, 1962. The Constitution (Dadra and Nagar Haveli) Scheduled Tribes Order, 1962. The Constitution (Pondichery) Scheduled Caste Order, 1964 The Constitution (Uttar Pradesh) (Scheduled Tribes) Order, 1967 The Constitution (Goa, Daman & Diu) Scheduled Caste Order, 1968. The Constitution (Goa, Daman & Diu) Scheduled Tribes Order, 1968. The Constitution (Nagaland) Scheduled Tribes Order, 1970. The Constitution (Sikkim) Scheduled Caste Order, 1978. The Constitution (Sikkim) Scheduled Tribes Order, 1978.

% 2. Applicable in the case of Scheduled Caste/Schedule Tribe persons who have migrated from one State/ UnionTerritory Administration:This certificate is issued on the basis of the Scheduled Caste/Scheduled Tribe certificate issued to Shri /Smt*...................................father/mother of Shri/Smt/Kum*...........................of village/town*...................... inDistrict/Division* of the State/Union Territory* ........................ who belongs to the...............caste/tribe which isrecognised as a Scheduled Caste/Scheduled Tribe* in the State/Union Territory* ......................... issued by the (name ofprescribed authority) vide their No.................date.......... % 3. Shri*/Smt.*/Kum* ........................... and/or his/her* familyordinary reside(s) in village/town* ..................... of the State/Union Territory of......................

Signature............................Place ....................... State/Union Territory **Designation............................Date ....................... (With seal of Office)

Please delete the words which are not applicable. Please quote specific Presidential Order.% Delete the paragraph which is not applicable.** Should be signed by the Authorities empowered to issue Scheduled Caste/Scheduled Tribe certificates as specified above.

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

65

Note:-

The information will appear in the website strictly as per time schedulelaid down in the Prospectus. Telephonic queries / written requests priorto the scheduled date mentioned in the Prospectus regarding receipt ofapplication, acceptance, hoisting of admit cards etc. will not beentertained.

For enquiries relating to Entrance Examination please contact:Assistant Controller (Exams)

Examination SectionAll India Institute of Medical Sciences (AIIMS)

Ansari Nagar, New Delhi -110 608Tel: 26589900, 26588500 Extn. 6421, 4499, 6422

Fax: 011 2658 8789www.aiimsexams.org

AIIM

SPh

.D. P

ROGR

AMM

E JU

LYBA

TCH

2017

PRO

SPEC

TUS

66

DISCLAIMER

The prospectus is a compilation of information obtained and collated from Examination andAcademic Sections of AIIMS, New Delhi, other new AIIMS and related sources. Due care hasbeen taken to faithfully reproduce the information provided by various sources.

The AIIMS, New Delhi disclaims any liability towards any individual or group of individualsfor any loss or damages caused due to him/her arising out of any action taken on the basisof any information contained in this prospectus that may be due to inadvertent omissions orerrors or for any other reason whatsoever.

The AIIMS, New Delhi reserves the right to suitably modify, update or delete or add any partof the prospectus as may be considered necessary by the competent authorities.